

## 1 **Biallelic variants in *ARHGAP19* cause a motor-predominant neuropathy with asymmetry and** 2 **conduction slowing**

3 Natalia Dominik<sup>1#</sup>, Stephanie Efthymiou<sup>1#§</sup>, Christopher J. Record<sup>1</sup>, Xinyu Miao<sup>2</sup>, Renee Lin<sup>1</sup>, Jevin  
4 Parmar<sup>3</sup>, Annarita Scardamaglia<sup>1</sup>, Reza Maroofian<sup>1</sup>, Gabriel Aughey<sup>4</sup>, Abigail Wilson<sup>4</sup>, Simon Lowe<sup>4</sup>,  
5 Riccardo Curro<sup>1</sup>, Ricardo P. Schnekenberg<sup>1</sup>, Shahryar Alavi<sup>1</sup>, Leif Leclaire<sup>2</sup>, Yi He<sup>2</sup>, Kristina  
6 Zhelchenska<sup>1</sup>, Yohanns Bellaiche<sup>5</sup>, Isabelle Gaugué<sup>5</sup>, Mariola Skorupinska<sup>1</sup>, Liedewei Van de  
7 Vondel<sup>6,7</sup>, Sahar I. Da'as<sup>8</sup>, Valentina Turchetti<sup>1</sup>, Serdal Güngör<sup>9</sup>, Ehsan Ghayoor Karimiani<sup>10,11</sup>, Camila  
8 Armirola Ricaurte<sup>12,13</sup>, Haluk Topaloglu<sup>14</sup>, Albena Jordanova<sup>12,13,15</sup>, Mashaya Zaman<sup>16</sup>, Selina H.  
9 Banu<sup>16</sup>, Wilson Marques<sup>17</sup>, Pedro José Tomaselli<sup>18</sup>, Busra Aynekin<sup>1</sup>, Ali Cansu<sup>19</sup>, Huseyin Per<sup>20</sup>, Ayten  
10 Güleç<sup>20</sup>, Javeria Raza Alvi<sup>21</sup>, Tipu Sultan<sup>21</sup>, Arif Khan<sup>22,23</sup>, Giovanni Zifarelli<sup>24</sup>, Shahnaz Ibrahim<sup>25</sup>, Grazia  
11 M.S. Mancini<sup>26</sup>, M. Mahdi Motazacker<sup>27</sup>, Esther Brusse<sup>26</sup>, Vincenzo Lupo<sup>28</sup>, Teresa Sevilla<sup>29,30</sup>, A Nazlı  
12 Başak<sup>31</sup>, Seyma Tekgul<sup>31</sup>, Robin Palvadeau<sup>31</sup>, Jonathan Baets<sup>6,7,32</sup>, Yesim Parman<sup>33</sup>, Arman Çakar<sup>33</sup>,  
13 Rita Horvath<sup>34,35</sup>, Tobias B. Haack<sup>36,37</sup>, Jan-Hendrik Stahl<sup>38,39</sup>, Kathrin Grundmann-Hauser<sup>36,37</sup>,  
14 Joohyun Park<sup>36,37</sup>, Stephan Züchner<sup>40,41</sup>, Nigel G. Laing<sup>3</sup>, Lindsay Wilson<sup>1</sup>, Alexander M. Rossor<sup>42</sup>,  
15 James Polke<sup>43</sup>, Fernanda Barbosa Figueiredo<sup>44</sup>, André Luiz Pessoa<sup>45</sup>, Fernando Kok<sup>44</sup>, Antônio  
16 Rodrigues Coimbra-Neto<sup>46</sup>, Marcondes C. França Jr<sup>46</sup>, Yalda Jamshidi<sup>47</sup>, Gianina Ravenscroft<sup>3</sup>, Sherifa  
17 Ahmed Hamed<sup>48</sup>, Wendy K. Chung<sup>49</sup>, Daniel P. Osborn<sup>50</sup>, Michael Hanna<sup>1</sup>, Andrea Cortese<sup>1</sup>, Mary M.  
18 Reilly<sup>1#</sup>, James E. C. Jepson<sup>4#</sup>, Nathalie Lamarche-Vane<sup>2,51#</sup>, Henry Houlden<sup>1#</sup>

- 19
- 20 1. Department of Neuromuscular Disease, UCL Queen Square Institute of Neurology, London,  
21 WC1N 3BG, UK.
  - 22 2. Department of Anatomy and Cell Biology, McGill University, Montréal, QC H3A 0C7, Canada.
  - 23 3. Harry Perkins Institute of Medical Research, Centre for Medical Research, University of  
24 Western Australia, Perth, Western Australia, Australia.
  - 25 4. Department of Clinical and Experimental Epilepsy, UCL Queen Square Institute of Neurology,  
26 London, UK.
  - 27 5. Team "Polarity Division and Morphogenesis" INSTITUT CURIE, France.
  - 28 6. Translational Neurosciences, Faculty of Medicine and Health Sciences, University of  
29 Antwerp, Antwerp, Belgium.
  - 30 7. Laboratory of Neuromuscular Pathology, Institute Born-Bunge, University of Antwerp,  
31 Antwerp, Belgium.
  - 32 8. Department of Human Genetics, Sidra Medicine, Doha, Qatar.
  - 33 9. Inonu University, Faculty of Medicine, Turgut Ozal Research Center, Department of Pediatric  
34 Neurology, Malatya, Turkey.
  - 35 10. Department of Molecular Genetics, Next Generation Genetic Polyclinic, Mashhad, Iran.
  - 36 11. Molecular and Clinical Sciences Institute, St. George's, University of London, Cranmer  
37 Terrace, London, SW17 ORE, UK.
  - 38 12. Molecular Neurogenomics group, VIB Center for Molecular Neurology, VIB, Antwerp,  
39 Belgium.
  - 40 13. Molecular Neurogenomics group, Department of Biomedical Sciences, University of  
41 Antwerp, Antwerp, Belgium.
  - 42 14. Department of Pediatric Neurology, Hacettepe University, Ankara, Turkey.
  - 43 15. Department of Medical Chemistry and Biochemistry, Medical University-Sofia, 1431, Sofia,  
44 Bulgaria.
  - 45 16. Department of Pediatric Neurology, Dr. M.R. Khan Shishu (Children) Hospital and ICH,  
46 Mirpur, Dhaka, Bangladesh.
  - 47 17. Department of Neurosciences, School of Medicine of Ribeirão Preto, University of São Paulo,  
48 São Paulo, Brazil.
  - 49 18. Clinical Hospital of Ribeirão Preto, Department of Neurosciences and Behaviour Sciences,  
50 University of São Paulo, Ribeirão Preto, Brazil.

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

- 51 19. Department of Pediatric Neurology, Faculty of Medicine, Farabi Hospital, Karadeniz  
52 Technical University, Trabzon, Turkey.
- 53 20. Department of Pediatric Neurology, Erciyes University, Kayseri, Turkey.
- 54 21. Children's Hospital & the Institute of Child Health, Lahore, Pakistan.
- 55 22. Pediatric Neurology, Neuropedia Hospital, Dubai, ARE.
- 56 23. Pediatric Neurology, Mohammed Bin Rashid University of Medicine and Health Sciences,  
57 Dubai, ARE.
- 58 24. CENTOGENE GmbH, Am Strande 7, 18055 Rostock, Germany.
- 59 25. Department of Pediatrics and Child Health, Aga Khan University, Karachi, Pakistan.
- 60 26. Department of Clinical Genetics, ErasmusMC University Medical Center, Dr.Molewaterplein  
61 40, 3015GD Rotterdam, The Netherlands.
- 62 27. Laboratory of Genome Diagnostics, Department of Human Genetics, Amsterdam UMC,  
63 University of Amsterdam, Meibergdreef 9, 1105 AZ, Amsterdam, the Netherlands.
- 64 28. Rare Neurodegenerative Diseases Laboratory, Centro de Investigación Príncipe Felipe (CIPF),  
65 46012 Valencia, Spain.
- 66 29. Hospital Universitari i Politècnic La Fe & IIS La Fe, Neuromuscular Diseases Unit, Department  
67 of Neurology, Valencia, Spain.
- 68 30. Universitat de València, Valencia, Spain. Centro de Investigación Biomédica en Red de  
69 Enfermedades Raras (CIBERER), Spain.
- 70 31. Suna and İnan Kıraç Foundation, Neurodegeneration Research Laboratory (NDAL), Research  
71 Center for Translational Medicine (KUTTAM), Koç University School of Medicine, Istanbul,  
72 Turkey.
- 73 32. Neuromuscular Reference Centre, Department of Neurology, Antwerp University Hospital,  
74 Antwerp, Belgium.
- 75 33. Department of Neurology, Istanbul Medical School, Istanbul University, Istanbul, Turkey.
- 76 34. Department of Clinical Neurosciences, School of Clinical Medicine, University of Cambridge,  
77 Cambridge Biomedical Campus, Cambridge, UK.
- 78 35. Department of Clinical Neurosciences, John Van Geest Centre for Brain Repair, School of  
79 Clinical Medicine, University of Cambridge, Cambridge, UK.
- 80 36. Center for Rare Disease, University of Tübingen, Tübingen, Germany.
- 81 37. Institute of Medical Genetics and Applied Genomics, University of Tübingen, Tübingen,  
82 Germany
- 83 38. Department of Epileptology, Center of Neurology, University of Tübingen, Germany.
- 84 39. Hertie Institute for Clinical Brain Research, University of Tübingen, Tübingen, Germany.
- 85 40. John P. Hussman Institute for Human Genomics, University of Miami, Miami, FL, USA.
- 86 41. Dr. John T. Macdonald Foundation Department of Human Genetics, University of Miami,  
87 Miami, FL, USA.
- 88 42. Centre for Neuromuscular Diseases, Department of Neuromuscular Diseases, UCL Queen  
89 Square Institute of Neurology, London, UK.
- 90 43. Neurogenetics Laboratory, The National Hospital for Neurology and Neurosurgery and the  
91 North Thames Genomics Laboratory Hub, London, UK.
- 92 44. Mendelics Genomic Analysis, São Paulo, SP, Brazil.
- 93 45. Universidade Federal Do Ceara - UFC and Hospital Infantil Albert Sabin, Fortaleza, Brazil.
- 94 46. Department of Neurology, School of Medical Sciences, University of Campinas (UNICAMP),  
95 Campinas, SP, Brazil.
- 96 47. Molecular and Clinical Sciences Institute, St. George's, University of London, SW17 0RE, UK.
- 97 48. Department of Neurology and Psychiatry, Faculty of Medicine, Assiut University, Assiut,  
98 Egypt.
- 99 49. Department of Pediatrics, Boston Children's Hospital, Harvard Medical School, Boston, MA,  
100 USA.

101 50. Genetics Sections, Molecular and Clinical Sciences Institute, St George's University of  
102 London, Cranmer Terrace, London, SW17 0RE, UK.

103 51. Cancer Research Program, Research Institute of the McGill University Health Centre,  
104 Montréal, QC H4A 3J1, Canada.

105

106 #Contributed equally

107 §Correspondence to Dr. Stephanie Efthymiou, Department of Neuromuscular Disorders, UCL Queen  
108 Square Institute of Neurology, UCL, London, WC1N 3BG, UK, s.efthymiou@ucl.ac.uk

## 109 Abstract

110 Charcot-Marie-Tooth Disease is a clinically and genetically heterogeneous group of hereditary  
111 neuropathies, with over 100 causative genes identified to date. Despite progress in genetic  
112 sequencing, around a quarter of patients remain unsolved. Through international collaborations, we  
113 identified 16 recessive variants in Rho GTPase activating protein 19 (*ARHGAP19*) causing motor-  
114 predominant neuropathy with conduction slowing in 25 individuals from 20 unrelated multi-ancestry  
115 families. *ARHGAP19* is a GTPase-activating protein with activity towards RhoA. *In vitro* biochemical  
116 assays revealed that variants located within the GAP domain cause loss of GAP activity. iPSc-derived  
117 motor neurons exhibited 50% knockdown of *ARHGAP19* protein. *In vivo* genetic perturbations of the  
118 *Drosophila melanogaster ARHGAP19* ortholog *RhoGAP54D* reduced self-driven locomotor activity  
119 and startle responses to visual stimuli. Zebrafish loss-of-function models similarly exhibited  
120 movement deficits, coupled with increased motor neuron axonal branching but shorter caudal  
121 primary motor neurons. Together, these findings establish *ARHGAP19* as a novel cause of early-  
122 onset neuropathy through a loss-of-function mechanism.

123

124 **Keywords:** neuropathy, Charcot-Marie-Tooth, Rho/ROCK pathway, next generation sequencing

125

126 **Running title:** *ARHGAP19* cause a motor-predominant neuropathy

127 Number of figures: 7

128 Number of tables: 1

129 Number of supplementary items: 14 (9 Tables, 5 Figures)

130

## 131 Introduction

132 Charcot-Marie-Tooth disease (CMT), also called hereditary motor and sensory neuropathy (HMSN) is  
133 the most prevalent Mendelian inherited neuropathy. Notably, inherited peripheral neuropathies are  
134 amongst the most frequently inherited neurologic diseases. The prevalence of CMT varies amongst  
135 populations but is estimated at around 1 in 2,500 individuals (1).

136 Patients with CMT can range from mildly affected to severely disabled and the disease presents with  
137 progressive weakness and atrophy of muscles, especially in distal limbs. Often foot abnormalities  
138 such as *pes cavus* or hammer toes may be associated with the disease. Symptoms of CMT overlap  
139 between neuropathies and subtypes of CMT. Despite many genes being associated to inherited  
140 CMT, there remains a large proportion of genetically unexplained cases. However, family history,  
141 nerve conduction studies and thorough clinical evaluation can aid differential diagnosis (2).

142

143 The Rho family of small GTPases is composed of 20 members that include RhoA, Rac1, and CDC42.  
144 Rho GTPases act as molecular switches by cycling between inactive guanine nucleotide diphosphate  
145 (GDP) bound state and active, triphosphate (GTP) bound state and are involved in signalling  
146 pathways that control actin cytoskeleton reorganisation, cell adhesion, migration, and cell division.  
147 The activity of Rho GTPases is tightly regulated by three classes of proteins, Guanine nucleotide  
148 Exchange Factors (GEFs) which facilitate the exchange from GDP to GTP; GTPase-Activating Proteins  
149 (GAPs) which stimulate the intrinsic GTPase activity, resulting in hydrolysis of GTP and protein  
150 inactivation; and Guanine Nucleotide Dissociation Inhibitors (GDIs) which sequester and maintain

151 Rho GTPases inactive in the cytoplasm(3) (4). In humans, over 66 RhoGAPs and 80 RhoGEFs have  
152 been identified for 20 members of Rho family that they can act on, and many are implicated in  
153 neurological diseases, including CMT (4). For example, *PLEKHG5*, a GEF gene that regulates  
154 autophagy of synaptic vesicles in axonal terminals, is associated with CMT (5). Furthermore, variants  
155 in *MYO9B*, a RhoGAP gene, have recently been shown to cause CMT type 2 (CMT2) and optic  
156 atrophy. Whether CMT can be caused by mutations in other regulators of Rho GTPases, however,  
157 remains an open question.

158  
159 Here, we report the clinical phenotypes associated with biallelic, autosomal recessive variants in  
160 *ARHGAP19* in 25 individuals with CMT from 20 families. *ARHGAP19* is a small, 494 amino acid (AA)  
161 RhoGAP protein, displaying GAP activity towards RhoA but not Rac1 and Cdc42, thus acting as a  
162 negative regulator of the RhoA/ Rho-associated kinase (ROCK) pathway. *ARHGAP19* has previously  
163 been shown to have an essential role in T-lymphocyte cytokinesis and phosphorylation by kinases  
164 such as ROCK at Ser422 and CDK1 at Thr404 and Thr476 is essential for its role in the control of cell  
165 division (3, 6). We provide mechanistic evidence for the contribution of variants to CMT suggesting a  
166 loss of function (LOF) mechanism through the use of individual patient cell lines, *in vitro* GAP assay,  
167 *in vivo Drosophila melanogaster* and *Danio rerio* knockdown models as well as *in-silico* molecular  
168 modelling. Both *Drosophila* and zebrafish LOF models exhibit significant motor defects, while  
169 zebrafish model indicates an impact of *ARHGAP19* LOF on motoneuron length and branching.

170

## 171 **Methods**

### 172 **Study Participants**

173 Individuals were recruited via an international collaborative network of research and diagnostic  
174 sequencing laboratories. Samples and clinical information were obtained, with informed consent,  
175 from each institution using local institutional review board (IRB) ethics for functional analysis of  
176 human DNA, fibroblasts and biomaterial. Clinical data collection involved a detailed review of  
177 medical records, photographs, videos, and phone interviews, as well as a clinical re-evaluation of  
178 nerve conduction studies by a neurologist. GeneMatcher and RD-Connect (GPAP) platform facilitated  
179 the identification of additional patients. Table 1 and Supplementary table 1 summarize the clinical  
180 details of the included cases. Study subject IDs used are for the purpose of this study and are not  
181 known to anyone outside the research group.

182

### 183 **Next generation sequencing**

184 Genomic DNA was extracted from peripheral blood samples of subjects and parents according to  
185 standard procedures. Exome sequencing on DNA of subjects P2, P3, P12, P15, P18 was performed as  
186 described elsewhere (7) in Macrogen, Korea. Briefly, target enrichment was performed with 2 µg  
187 genomic DNA using the SureSelectXT Human All Exon Kit version 6 (Agilent) to generate barcoded  
188 whole-exome sequencing libraries. Libraries were sequenced on the HiSeqX platform (Illumina) with  
189 50x coverage. Quality assessment of the sequence reads was performed by generating QC statistics  
190 with FastQC. The bioinformatics filtering strategy included screening for only exonic and  
191 donor/acceptor splicing variants. In accordance with the pedigree and phenotype, priority was given  
192 to rare variants (<0.01% in public databases, including 1000 Genomes project, NHLBI Exome Variant  
193 Server, Complete Genomics 69, and Exome Aggregation Consortium [ExAC v0.2]) that were fitting a  
194 recessive (homozygous or compound heterozygous) or a *de novo* model and/or variants in genes  
195 previously linked to neuropathy, developmental delay, and other neurological disorders. Next  
196 generation sequencing for other samples was carried out using a number of methods with different  
197 analysis platforms and pipelines used depending on the centre where sequencing was performed  
198 (Supplementary Table 2). Recommendations of the Human Genome Variation Society were used to  
199 describe the cDNA and protein sequence variants using NM\_032900.6 and NP\_116289.4 as the  
200 reference. All the candidate variants were further verified, and family segregation was performed via  
201 Sanger sequencing in-house or in the referring centres. Homozygosity mapping was performed on

202 Automap(8) and haplotype analysis was performed by plotting a colour banding of the variants  
203 flanking the pathogenic ARHGAP19 variants for affected individuals and control samples. By  
204 comparing the banding patterns of patients and controls, the status of being a founder/recurrent  
205 variant was investigated. In the case of founder variants, we estimated the age of the most recent  
206 common ancestor (MRCA) using the length of shared haplotypes between patients(9).

207

### 208 **Multiple sequence alignment**

209 To examine the conservation of substituted amino acid positions, we performed multiple sequence  
210 alignments of ARHGAP19 across multiple different species. ARHGAP19 protein sequences for each  
211 species were retrieved from UniProt using their respective accession codes (Supplementary Table 3).  
212 Alignments were performed using the MAFFT algorithm in Jalview (v2.11.2).

213

### 214 **Protein structure modelling and in silico mutagenesis**

215 The predicted wild-type ARHGAP19 protein structure was retrieved from the AlphaFold Protein  
216 Structure Database (10) using its UniProt accession code (Q14CB8). Three-dimensional protein  
217 structures were visualised using PyMol (v.2.5.2). To examine variant effects on three-dimensional  
218 protein structure, *in silico* mutagenesis for identified missense substitutions was performed through  
219 the PyMol ‘mutagenesis’ function. For nonsense and frameshift variants, mutant protein structures  
220 were generated using the open-source AlphaFold v2.0 (AlphaFold2) pipeline (10) with the input  
221 being FASTA files of the mutant amino acid sequences. The resultant protein structures were then  
222 aligned to the wild-type ARHGAP19 protein structure within PyMol. AlphaMissense substitution  
223 scores for identified *ARHGAP19* missense variants were downloaded and extracted from resources  
224 generated by Cheng *et al* (11).

### 225 **Calculation of free energy changes**

226 To investigate the impact of *ARHGAP19* variants on protein stability, free energy changes between  
227 the wild-type and mutant proteins were calculated using FoldX v5.0.(12) Free energy change  
228 predictions were only performed on missense substitutions within high confidence regions (pLDDT >  
229 90) of the AlphaFold2-predicted protein structure.(13) The AlphaFold2 derived wild-type ARHGAP19  
230 protein structure was energy minimised and prepared for mutagenesis with the ‘RepairPDB’ and  
231 ‘BuildModel’ commands in FoldX, respectively. Subsequent free energy calculations were performed  
232 with the ‘Stability’ command, and differences in free energy were determined by subtracting the  
233 free energy value of the wild-type protein monomer from that of the mutant protein ( $\Delta G_{MUT} - \Delta G_{WT}$ ).  
234 Calculations were replicated 10 times with default parameters for each substitution. Substitutions  
235 were classified as having a destabilising effect on protein folding if the free energy difference ( $\Delta\Delta G$ )  
236 was >1.6 kcal/mol (12, 14, 15).

237

### 238 **Cell culture of primary dermal fibroblasts**

239 Primary dermal fibroblasts were obtained from skin biopsies of subjects in family 5 (P5 (F5-II:2)  
240 (c.419G>A), family 6 (P6 (F6-II:7) (c.203T>C) and family 10 (P11 (F10-II:1) (c.85A>G) and age/ gender  
241 matched control individuals. Fibroblasts were cultured in Dulbecco’s modified Eagle medium  
242 (DMEM; Thermo Fisher Scientific) supplemented with 10% fetal bovine serum (FBS; GE Healthcare)  
243 and penicillin-streptomycin (100 U/mL and 100 mg/mL, respectively; Thermo Fisher Scientific). For  
244 all experiments, the same passage number of subject and control fibroblasts was used. Primary  
245 fibroblasts were regularly tested for mycoplasma contamination and confirmed to be mycoplasma  
246 free.

247

### 248 **Generation and culture of iPSCs**

249 Healthy control iPSCs were obtained through the *StemBANCC Consortium*. Patients-derived  
250 fibroblasts (P5 (F5-II:2) and P6 (F6-II:7)) were reprogrammed by non-integrating Sendai viral vectors  
251 at Oxford StemTech (Oxford, United Kingdom). All iPSC lines were subject to quality control checks,

252 including flow cytometry for pluripotency markers, global screening array karyotyping, and  
253 mycoplasma test. iPSCs were plated in Matrigel-coated 6-well plates and maintained in mTesR1  
254 (StemCell Technologies).

255

#### 256 **Differentiation of iPSCs to spinal motor neurons**

257 iPSCs were differentiated into MNs using a protocol previously published (16). Briefly, iPSCs were  
258 dissociated with accutase and resuspended in a 10mm<sup>2</sup> Petri dish to form embryoid bodies (EBs).  
259 Differentiation medium consisted of (1:1 DMEM/F12-Neurobasal media, supplemented with N2,  
260 B27, 2 mM L-glutamine, 1% Pen-Strep, 0.1 mM  $\beta$ -ME; all from ThermoFisher Scientific), with 10  $\mu$ M  
261 Y-27632 (Tocris), 0.1  $\mu$ M LDN 193189, 20  $\mu$ M SB431542, and 3  $\mu$ M CHIR-99021 (Cambridge  
262 Bioscience). Media was replaced every 2-3 days, with the addition of the following small molecules:  
263 100 nM retinoic acid (RA, Sigma Aldrich) from day 2; 500 nM Smoothened Agonist (SAG, Sigma  
264 Aldrich) from day 4; 10  $\mu$ M DAPT (Cambridge Bioscience) from day 9. LDN 193189, SB431542 and  
265 CHIR-99201 were discontinued on day 7. The neurotrophic factors BDNF, CNTF and GDNF  
266 (Peprotech) were added to the differentiation medium from day 11, at a concentration of 10 ng/mL.  
267 On day 14, EBs were dissociated, and post-mitotic neurons were seeded on poly-L-ornithine (Sigma  
268 Aldrich) and laminin (Biotechne) coated plates. Eleven days after seeding cells were fixed for  
269 immunocytochemistry and harvested for RNA and protein extraction.

270

#### 271 **Migration assay**

272 Migration assays were performed and analysed as previously described(17). 100,000 cells were  
273 resuspended in serum-free medium and plated on the top chamber (24-well transwell insert, Falcon:  
274 353097). Cells were incubated at 37°C for 24h, which allowed migration towards the bottom  
275 chamber containing complete medium with 10% FBS. Cells on the bottom surface of the insert  
276 were fixed in 10% formalin (BioShop: FOR201) and stained with a crystal violet solution. Ten  
277 images were taken for each transwell insert using a Nikon inverted microscope camera with a  
278 10X objective lens (Nikon Eclipse TE300 Inverted microscope). Quantitative analysis was assessed  
279 using Image J software. Data represent the fold change relative to wild type cells obtained from  
280 at least three independent experiments.

281

#### 282 **Wound healing scratch assay**

283 15,000 cells were seeded in 100  $\mu$ L of culture medium into sterile transparent 96-well plates and  
284 incubated for 24h. A scratch wound was made in the confluent cell monolayer of each well using the  
285 IncuCyte 96-well WoundMaker from Essen Bioscience as described in manufacturer's manual. After  
286 carefully removing the cellular debris, 100  $\mu$ L of culture medium was added to each well. Cell images  
287 were captured every two hours using IncuCyte Live-Cell Imaging Systems (Essen BioScience, USA).  
288 Images were analysed using the IncuCyte S3 software (2019A) to calculate cell confluency over time.

289

#### 290 **RNA isolation, cDNA synthesis, and quantitative real-time PCR (RT-qPCR)**

291 Total RNA was extracted from cultured primary fibroblasts of subjects P5 (F5-II:2), P6 (F6-II:7), and  
292 P11 (F10-II:1) and controls and from iPSC motor neuron of subjects P5 (F5-II:2) and P6 (F6-II:7) and  
293 controls (using QIAGEN RNeasy extraction kit). gDNA purification was performed with DNA-free™  
294 DNase (ThermoFisher). RNA concentration and purity of the samples were assessed using  
295 NanoDrop equipment (NanoDrop Technologies Inc., Wilmington, DE). 0.5  $\mu$ g total RNA was reverse  
296 transcribed (Superscript III, ThermoFisher). Technical triplicates of RT-qPCR samples were prepared  
297 as a 10  $\mu$ L approach with the Fast SYBR™ Green Master Mix (ThermoFisher), 500 nM of each primer,  
298 and 1  $\mu$ L of the reverse transcription reaction. Primer sequences for RT-qPCR are described in  
299 Supplementary Table 6. RT-qPCR was performed using the QuantStudio 3 Real-Time PCR System  
300 (Thermo Fisher Scientific) equipped with QuantStudio Design&Analysis Software v1.4.3 (Thermo  
301 Fisher Scientific). The PCR conditions included a pre-run at 95°C for 5 min, followed by 40 cycles of  
302 30 s at 95°C, 30 s at 58°C and 45 s at 72°C. PCR amplification specificity was determined by melting

303 curve analysis with a range from 60°C to 95°C. The values of the cycle threshold (CT) of the target  
304 mRNAs were normalized to the mRNA of *RPL18*. For relative gene expression, the comparative cycle  
305 threshold ( $\Delta\Delta CT$ ) values were calculated with the QuantStudio Design&Analysis Software (Thermo  
306 Fisher Scientific) with *RPL18* as housekeeping gene and expressed as x-fold change to controls.

307

### 308 **RNA sequencing and analysis**

309 RNA sequencing was performed on RNA from subjects P5 (F5-II:2), P6 (F6-II:7) and P11 (F10-II:1) as  
310 well as 3 controls using the Illumina TruSeq Stranded mRNA Library Prep kit. Pools were sequenced  
311 using the Illumina NovaSeq 6000 Sequencing system to generate 100 bp paired-end reads with an  
312 average read depth of ~100 million reads per sample. RNA sequencing raw data was mapped to  
313 human reference genome assembly hg38 using STAR (18). Gene count tables were imported into R  
314 environment to analyse differential gene expression patterns using DESeq2 package (19). For gene  
315 enrichment analysis, pathfindR package was employed (20). Briefly, Biogrid database was used for  
316 mapping the genes to protein-protein interaction network, with their associated p-values. The  
317 resulting active subnetworks were filtered based on the significant genes they contain. The filtered  
318 subnetworks were then enriched by the related cellular pathways. This was followed by hierarchical  
319 clustering to group biologically relevant pathways. Major pathways with enrichment fold greater  
320 than 2 were selected for plotting per sample expression scores.

### 321 **Western blotting**

322 Fibroblasts of subjects P5 (F5-II:2), P6 (F6-II:7) and P11 (F10-II:1) and controls and fibroblast-derived  
323 iPSc motor neurons of patients subjects P5 (F5-II:2) and P6 (F6-II:7) and controls were harvested in  
324 ice-cold RIPA buffer (50 mM Tris-HCl, pH 8.0; 150 mM NaCl; 1% NP-40; 0.5% DOC [sodium  
325 deoxycholate]; 0.1% SDS [sodium dodecyl sulfate]) supplemented with Mini Protease Inhibitor  
326 (Roche) and lysed for 60 min on ice. Cell debris was removed by centrifugation for 10 min. Protein  
327 extracts were separated on 4-12 % SDS polyacrylamide gel under denaturing conditions and  
328 transferred to polyvinylidene fluoride membranes. Membranes were blocked followed by incubation  
329 with a ARHGAP19 primary antibody (Santa Cruz Biotechnology; 1:500) overnight at 4°C. After  
330 washing, membranes were incubated HRP-linked anti-mouse secondary antibody (#G-21040  
331 Invitrogen; 1:10,000) at room temperature for 1 h. After washing, immunoblots were digitally  
332 imaged using a Machine iBright 750 (Invitrogen). Exposure time was optimized to avoid saturation.  
333 Bands were automatically defined, and intensities were determined using the build-in band  
334 detection tool of the Image Lab v6.0 software (Bio-Rad). GAPDH (ab9484, Abcam; 1:10000) was used  
335 as a loading control. Blots were repeated in duplicates and statistics were performed using Graph  
336 Pad Prism. The significance between the variables was shown based on the p value obtained (ns  
337 indicates  $p > 0.05$ , \* $p < 0.05$ , \*\* $p < 0.005$ , \*\*\* $p < 0.0005$ , \*\*\*\* $p < 0.00005$ ).

338

### 339 **Protein expression and purification**

340 Recombinant wild type and mutant GST-tagged ARHGAP19 GAP domain proteins were expressed in  
341 BL21 (DE3) bacteria and purified using glutathione-sepharose beads as previously described (21).  
342 PreScission protease (GenScript) was used for the cleavage of the GST tag and elution of the purified  
343 ARHGAP19 GAP proteins. Eluted proteins were concentrated using Amicon Ultra-4 centrifugal filters  
344 (MilliporeSigma), resolved by SDS-PAGE followed by Coomassie blue staining. Proteins were  
345 quantified using bovine serum albumin (BSA) as standard.

346

### 347 **In vitro GAP assay**

348 The GAP activity of ARHGAP19 wild type and protein mutants was assessed using the RhoGAP assay  
349 biochem kit (BK105, Cytoskeleton) according to manufacturer's instructions and recommendations.  
350 Briefly, 1.5  $\mu\text{g}$  of purified ARHGAP19 protein was mixed with His-RhoA protein and GTP for 20 min at  
351 37 °C. CytoPhos reagent was added to the reaction mixture for 10 min at room temperature before  
352 measuring the absorbance at 650nm with Infinite M200 Pro Microplate reader (TECAN).

353

### 354 ***Drosophila* stocks and husbandry**

355 Flies were raised on standard fly food at 25°C in 12 h light: 12 h dark cycles. All experiments and  
356 crosses were conducted in these conditions unless otherwise specified. The following *Drosophila*  
357 stocks were obtained from the Bloomington *Drosophila* stock center: *y[1] w[\*]; P{Act5C-GAL4-*  
358 *w}E1/CyO* (actin-Gal4; BDSC #25374), *[1] v[1]; P{y[+t7.7] v[+t1.8]=TRiP.HMS03522}attP40* (UAS-  
359 RhoGAP54D shRNA; BDSC #54051), *y[1] w[\*];*  
360 *Ti{GFP[3xP3.cLa]=CRIMIC.TG4.1}RhoGAP54D[CR02433-TG4.1]/SM6a* (RhoGAP54D-Gal4; BDSC  
361 #92267), *y[1] w[\*]; P{w[+mC]=tubP-GAL4}LL7/TM3, Sb[1] Ser[1]* (tubulin-Gal4; BDSC #5138), and  
362 *w[\*]; P{w[+mC]=UAS-Nslmb-vhhGFP4}3* (BDSC #38421). The RhoGAP54D::GFP fusion allele (*w[\*];*  
363 *RhoGAP54d:GFP:2Ma*; MKRS/TM6B) was generated via CRISPR-Cas9 gene editing, as described  
364 previously (22). The *w[\*]; P{Act5C-GAL4-w}E1/CyO* insertion was outcrossed into an isogenized  
365 background (iso31) for five generations, with the X-linked *y[1]* marker removed in the process  
366 (Supplementary Table 7).

367

### 368 **Generation of a *Drosophila RhoGAP54D* null allele**

369 The *RhoGAP54D*<sup>KO</sup> loss of function allele was generated using CRISPR/Cas9 mediated homologous  
370 recombination. We generated homologous recombination donor and guide plasmids to replace the  
371 *RhoGAP54D* reading frame from amino-acids (AA) T4 to L1004 (numbered according to the isoform  
372 RA, 1004 AA in length) by a *mw* gene flanked by two attP Phi31 recombination sites using the  
373 pCRISPR-del (23) and the pCFD5 (24) plasmids. pCFD5 was a gift from Simon Bullock (Addgene  
374 plasmid # 73914 ; <http://n2t.net/addgene:73914> ; RRID:Addgene\_73914). To generate the pCRISPR-  
375 del- *RhoGAP54D* targeting the *RhoGAP54D* locus, the genomic 5' HR1 (~1kb) and 3' HR2 (~1kb)  
376 regions were PCR amplified using the following primers: HR1 5'-

377 CCGGGCTAATTATGGGGTGTGCGCCCTTCGCGGATCTCCGTAGACGCCGTTTC and 5'-

378 ACTCAAAGGTTACCCAGTTGGGGCACTACTGCTTCCATGCAATCTGTGTGGTTTATCC, HR2 5'-

379 ACTCAAAGGTTACCCAGTTGGGGCACTACGACACGTTTAGCTTGCCGCG and 5'-

380 GCCCTTGAACGATTGACGCTCTTCTGTACAAGCCACCCACACTGAG to clone them in pCRISPR-del  
381 (underlined nucleotides matching the plasmid sequence used for cloning). We used 4 distinct gRNA,  
382 two in Nter and two in Cter to the *RhoGAP54D* locus, cloned in tandem in gRNA pCFD5 (Addgene

383 #73914) plasmid to generate 2 pCFD5-*RhoGAP54D* guide plasmids using the following primer: 5-  
384 GCGGCCCGGGTTCGATTCCCGGCCGATGCAAGATTGCATGGAAGCAACGAGTTTTAGAGCTAGAAATAGCAA

385 G and 5'-

386 ATTTAACTTGCTATTTCTAGCTCTAAAACTTTCGCCCGGATACTTCTCGTGACACCAGCCGGAATCGAAC as  
387 well as 5'-

388 GCGGCCCGGGTTCGATTCCCGGCCGATGCAAGATTGCATGGAAGCAACGAGTTTTAGAGCTAGAAATAGCAA  
389 G and 5'-

390 ATTTAACTTGCTATTTCTAGCTCTAAAACATCCATCGTTGCTTCCATGTGCACCAGCCGGAATCGAAC.

391 Cloning was performed by primer annealing and ligation, or by SLIC. All regions amplified by PCR as  
392 well as junctions between tag and genomic sequences were checked by sequencing. *RhoGAP54D*<sup>KO</sup>  
393 allele was then generated by co-injection of the pCRISPR-del- *RhoGAP54D* (300ng/ml) and each of  
394 the guide plasmid (25ng/ml) in embryos of the PBac{y+attP-9A}VK00027 (BDSC #51324) line.

395 Embryos injection was performed by BestGene transgenesis services. The *RhoGAP54D*<sup>KO</sup> genomic  
396 deletion and locus organization were confirmed by PCR and sequencing.

### 397 ***Drosophila* activity assays**

398 To quantify locomotion in adult male flies, the *Drosophila* Activity Monitor (DAM; Trikinetics inc.,  
399 MA, USA) was used as described previously(25). Individual flies were housed in glass tubes  
400 containing 4% sucrose and 2% agar, bisected by an infrared beam, allowing activity to be quantified  
401 as the number of beam breaks made by each fly over time. Fly movement was measured at 25°C  
402 across 24 h comprised of 12 h light and 12 h dark period, from which total activity and activity during  
403 ZT (zeitgeber time) 12-13 were quantified. Experiments were performed on 3-7 day old male flies. All  
404 flies were acclimatised to the DAM conditions for 48 h prior to the experimental period.



405

#### 406 ***Drosophila* immuno-histochemistry**

407 Adult brains were dissected and immuno-stained as described previously(26). Briefly, brains were  
408 fixed for 20 min at room temperature via incubation in 4% paraformaldehyde (MP Biomedicals), and  
409 blocked for 1 h in 5% normal goat serum in Phosphate Buffered Saline containing 0.3% Triton-X  
410 (Sigma-Aldrich) (0.3% PBT). Primary antibodies were as follows: mouse anti-Bruchpilot (BRP) (nc82,  
411 Developmental Studies Hybridoma Bank), 1:50; rabbit anti-dsRed (Clontech, Cat. no. #632496),  
412 1:1000. Secondary antibodies were: goat anti-rabbit AlexaFluor-555 (ThermoFisher, Cat. no.  
413 #A32732), 1:1000; and goat anti-mouse AlexaFluor-647 (ThermoFisher Cat. no. #A21236), 1:500.  
414 Brains were incubated in primary and secondary antibodies overnight at 4°C. Brains were washed  
415 then mounted and imaged in SlowFade Gold anti-fade mounting solution (ThermoFisher Scientific).  
416 Images were taken using a Zeiss LSM 710 confocal microscope with an EC 'Plan-Neoflar' 20x air  
417 objective. Images were analysed using ImageJ.

418

#### 419 **Quantitative PCR**

420 Total RNA was extracted from dissected brain tissue of *actin > UAS-RhoGAP54D* shRNA and *actin >*  
421 *UAS-mCherry* shRNA (control) adult male flies using standard phenol chloroform extraction. RNA  
422 concentration and purity were assessed using NanoDrop equipment (NanoDrop Technologies Inc.,  
423 Wilmington, DE). 0.5 µg of total RNA was reverse transcribed to generate cDNA (Superscript III,  
424 ThermoFisher). Technical duplicates of the qPCR samples were prepared as a 10 µL approach with  
425 the Fast SYBR™ Green Master Mix (ThermoFisher), using 500 nM of each primer (forward:  
426 ATGGAAGCAACGATGGATACG; reverse: CTCGTGACAGGGGAGATCGAA), and 1 µl of the reverse  
427 transcription reaction. qPCR was performed using the QuantStudio 3 Real-Time PCR System (Thermo  
428 Fisher Scientific) equipped with QuantStudio Design&Analysis Software v1.4.3 (Thermo Fisher  
429 Scientific). The PCR conditions included a pre-run at 95°C for 5 min, followed by 40 cycles of 30 s at  
430 95°C, 30 s at 58°C and 45 s at 72°C. PCR amplification specificity was determined by melting curve  
431 analysis with a range from 60°C to 95°C. The values of the cycle threshold (CT) of the target mRNAs  
432 were normalized to the mRNA of Rpl4 (forward primer: TCCACCTTGAAGAAGGGCTA; reverse primer:  
433 TTGCGGATCTCCTCAGACTT). For relative gene expression, the comparative cycle threshold ( $\Delta$ CT )  
434 values were calculated with the QuantStudio Design&Analysis Software (Thermo Fisher Scientific)  
435 with Rpl4 used as a control gene. *RhoGAP54D* expression was normalised to *Rpl4* and expressed as  
436 a fold change relative to *actin > UAS-mCherry* shRNA controls.

437

#### 438 ***Danio rerio* functional analyses**

439 Wild-type zebrafish, *Danio rerio*, were housed and bred within UCL Fish Facility at 28.5°C on a 14h  
440 day/10h dark cycle. All experiments were conducted under licences awarded by the UK Animal  
441 (Scientific Procedures) Act 1986 implemented by the Home Office in England. For whole-mount *in*  
442 *situ* hybridization, zebrafish embryos were first fixed in 4% paraformaldehyde (PFA/PBS) overnight at  
443 4°C, dechorionated, and dehydrated in methanol at -20°C. A T7 bacteriophage promoter containing  
444 amplicon of *arhgap19* was synthesised from cDNA libraries at three different developmental stages:  
445 24 hours post-fertilization (hpf), 48 hpf, and 5 days post-fertilization (dpf). A primer set was designed  
446 with the T7 bacteriophage promoter sequence incorporated at the 5' end of the reverse primer for  
447 antisense probe production (Forward primer: 5'-GGCCGAATTCTCACAGCTAC-3'; Revers primer: 5'-  
448 **TAATACGACTCACTATAGGT**CTTACACGCGCTGATGAAC-3'). A Digoxigenin-labeled antisense probe  
449 was synthesized using a DIG-RNA Labeling Kit (T7 polymerases, Roche). Whole-mount *in situ*  
450 hybridization (WISH) was carried out as previously described (27) on 48 hpf, 72 hpf, and 5 dpf larvae.  
451 For the color reaction, NBT/BCIP Stock Solution (Roche) was used in the staining buffer. The stain  
452 was fixed in methanol and embryos mounted in 3% methylcellulose for imaging.

453

454 The zebrafish *arhgap19* gene (ZDB-GENE-100922-157) is an ortholog of *Homo sapiens* ARHGAP19;  
455 there is 59.95 % nucleotides similarity and 55 % amino acid similarity between the zebrafish and

456 human loci. No zebrafish paralogs corresponding to ARHGAP19 exist. CRISPR/Cas9-mediated FO  
457 biallelic knockout was performed as described previously (28). Six crRNAs were designed according  
458 to their on-target and off-target scores. The six sgRNAs sequences were: 1) 5'-  
459 ACGCTCCTCAAGAGTTTCTT-3', 2) 5'-CAAGATGTCTGCTCACAACC-3', 3) 5'- CAAGAGTTTCTTGGGAGAAT-  
460 3', 4) 5'-GAACCCAAGACTCCCAACGC-3', 5) 5'-TGACTTTCATCCCAATGACG-3', 6) 5'-  
461 AGGCAACAAGACGAGTTTTC-3'. Each crRNA was annealed to tracrRNA and complexed to Alt-R S.p.  
462 HiFi Cas9 nuclease to form a ribonucleoprotein (RNP). A pool of three RNPs were co-injected into  
463 one to two-cell stage zebrafish embryos. For each RNP pool, 0.5nL and 1nL volumes were injected  
464 into the yolk of batches of embryos. At 5 dpf, three zebrafish larvae were randomly selected for  
465 genomic DNA extraction to determine the targeting efficiency by Illumina Miseq (Eurofins). PCR  
466 amplification targeting RNP cut sites were performed for each crRNA and products purified, pooled  
467 and sent for next generation sequencing. Primers included universal adaptors for MiSeq  
468 (Supplementary Table 5). Cut efficiency was calculated for each RNP using CRISPResso2 (29) .  
469 An antisense translational blocking Morpholino (MO, GeneTools.LLC) against the AUG-containing  
470 mRNA sequence (5'-GGCCATCTTTCATCTTCCGTTTGAA-3') and a splice MO targeting the Exon1-  
471 Intron1 (E1I1) boundary (5'-ATAAATCTTCGTTACCTTCTGTCTC-3') was designed to knockdown  
472 arhgap19 function. MOs were diluted to the desired working concentrations (3 ng, 4 ng, 6 ng, and  
473 8ng per embryo) before use. Microinjection was performed by injecting 0.5-1nL morpholino solution  
474 into one to two-cell stage embryos in the yolk. Dose dependent phenotyping was used to identify an  
475 appropriate concentration that balanced survival with specific phenotypic changes.

476

#### 477 ***Danio rerio* behavioural assays**

478 Zebrafish larvae at 5 dpf were transferred into individual wells of a square flat-bottomed 96-well  
479 plate. Baseline locomotor activity was recorded for a duration of 30 minutes and analysed using the  
480 DanioVision (Noldus, Netherlands) monitoring chamber, which was integrated with the EthoVision  
481 XT 14 video tracking software (Noldus, Netherlands). Plots were analysed for distance travelled (in  
482 millimeters), total time spent and velocity. For assessment of muscle integrity, zebrafish larvae at 5  
483 dpf were fixed and their skeletal muscle was analysed for total birefringence using polarized light  
484 microscopy on a Nikon SMZ1000 stereo microscope.

485

#### 486 ***Danio rerio* Immuno-histochemistry**

487 Zebrafish larvae at 5 dpf were permeabilized with 10ug/ml Proteinase in PBS Tween (0.2%, PBT)K,  
488 followed by 20 mins fixation in 4% PFA. Larvae were then blocked with goat serum (5% in PBT), and  
489 incubated with anti-tubulin mouse monoclonal antibody (1:500 dilution; T6793-2ML, Sigma)  
490 overnight at 4°C. After four washing steps (PBT), larvae were incubated with Alexa Fluor™ anti-  
491 mouse 568 secondary antibody (1:1000 dilution; A-11004, ThermoFisher) in the dark at 4°C. For  
492 nucleus detection, larvae were incubated with DAPI (1:1000 dilution; D1306, ThermoFisher) under  
493 dark conditions at 4°C. Embryos were washed again in PBT (four times) and imaged using a Nikon  
494 A1R confocal microscope to assess motor neuron morphology. Confocal fluorescent images were  
495 processed and code depth adjusted with FIJI/ImageJ while motor neuron quantification was  
496 conducted using the SNT plugin.

497

#### 498 **Statistical Analysis**

499 Statistical evaluations were carried out using IBM SPSS Statistics. One-way ANOVA and Welch's t-test  
500 were used for statistical comparisons between groups with calculated standard deviations/errors of  
501 the mean. For *Drosophila* work, we run non-parametric tests for normal distribution using Shapiro-  
502 Wilk test for normality. Normally distributed datasets were subject to tests as stated. Non-normal  
503 were subject to Mann-Whitney U-test or Kruskal-Wallis test with Dunn's post-hoc test (single or  
504 multiple comparisons respectively). Significant differences were determined at a threshold of  $p <$   
505 0.05. The corresponding p-values are provided in the figure legends.

506

507 **Data availability**

508 The data that supports the findings of this study are available within the paper and in the  
509 supplementary material. Whole-exome sequencing data are not publicly available due to privacy or  
510 ethical restrictions. The identified variants reported in this manuscript were submitted to the LOVD  
511 database (<https://databases.lovd.nl/shared/genes/ARHGAP19>), with the LOVD variant IDs:  
512 #0000971425, #0000971426, #0000971427, #0000971440, #0000971442, #0000971444,  
513 #0000971446, #0000971450, #0000971466, #0000971468, #0000971470, #0000971471,  
514 #0000971473, #0000971474, #0000971475, #0000971478, #0000971479 and #0000971480.

515 **Results**

516 **Genetic Findings**

517 We identified 20 unrelated families with 25 affected individuals harbouring biallelic variants in  
518 *ARHGAP19* (Figure 1B for variant schematic within the protein and Figure 2A for pedigrees). All  
519 variant alleles identified in the families were either absent or observed only as heterozygous at  
520 extremely low frequencies in over 1.5 million alleles across multiple publicly available and private  
521 genetic variant databases (range 0–0.003). Four variants (4/16, 25%) were observed in more than  
522 one family. Notably, p.His196Glnfs\*9, p.Leu68Pro, p.Gln151Lys and p.Leu228His variants were found  
523 in 2 independent Arab, 4 independent Turkish, and 2 independent Bangladeshi/Afghani families,  
524 respectively.

525  
526 Haplotype plots of homozygous regions encompassing *ARHGAP19* variants were compared to assess  
527 if the same causative variants are inherited from a common ancestor (Supplementary Figure 1). The  
528 chr10:97259559-A-T (p.Leu228His) and chr10:97263447-G-GT (p.His196Glnfs\*9) variants are  
529 recurrent since patients harbouring the shared variants have different haplotypes. Patients F14-II:2  
530 and F7-II:1 harbour the chr10:97263582-G-T variant (p.Gln151Lys) and share a large 3.4 MB long  
531 haplotype. MRCA analysis shows that this founder variant has emerged about 26 generations ago  
532 (equivalent to 520 years). Variant chr10:97265979-A-G (p.Leu68Pro) is the other founder variant  
533 that we detected in patients F15-II:3 and F6-II:7 who harbour the same haplotype. The shared  
534 homozygous region is 3.0 MB in length, and they have inherited the variant from a common  
535 ancestor back to about 29 generations ago (equivalent to 580 years).

536 **Clinical Delineation**

537 Table 1 summarises the core clinical features of affected probands with *ARHGAP19* defects (see  
538 Supplementary Table 1 for Neurophysiology and for detailed clinical vignettes please contact the  
539 corresponding author to request access to these materials). A total of 25 individuals were identified  
540 from 20 families and 9 (36%) were male. They were from a wide range of ancestral backgrounds  
541 including Pakistan, Turkey, Egypt, Syria, Bangladesh, Spain, Australia, Brazil, Iran, Dubai and  
542 Afghanistan. 72% (18/25) were born from consanguineous parents. The mean (median) age at  
543 symptom onset (AAO) was 9.9 (10.0) years, and at assessment was 22.8 (16.0) years. The presenting  
544 symptom was a motor deficit of the lower limbs in 91% (21/23), and 64% (14/22) had some form of  
545 clinical sensory involvement (symptoms or signs), but as the disease progressed it typically remained  
546 either exclusively motor or motor predominant. Patients typically had a length-dependent pattern  
547 (17/23, 74%, which includes those with only distal lower limb involvement) of lower motor neuron  
548 signs of areflexia and muscle atrophy, with foot drop. Lower limb-predominant disease was seen  
549 (distal > proximal weakness, with normal upper limbs) in 17% (4/23) and upper limb predominant  
550 disease seen in 9% (2/23). Foot deformity was present in 80% (16/20), with a recurrent, but not  
551 ubiquitous finding of increased sandal gap (access to photos of deformities mentioned can be  
552 accessed by contacting the corresponding author). However, the presence brisk knee jerks, and  
553 preserved lower limb reflexes each in 9% (3/23) respectively suggests some mild UMN involvement  
554 in these individuals. There were no consistent features outside of the peripheral nervous system.

555  
556 A prominent feature of the phenotype is its significant asymmetry in terms of limb involvement,  
557 seen at onset or at assessment in 61% (14/23). Two cases presented acutely with upper limb

558 weakness on a background of mild or subclinical widespread neuropathy. Neurophysiology  
559 (Supplementary Table 1) was performed in 20 individuals. Detailed numerical study data was  
560 available in 15/20; five cases had a report only. All had a motor neuropathy, with variable sensory  
561 involvement. Evidence of motor conduction slowing was seen or described in 50% (10/20) and  
562 conduction block in 20% of the studies with numerical data (3/15). Combining clinical and  
563 neurophysiological data the following phenotypes were seen: CMT-intermediate (CMTi) (2/25),  
564 CMT2 (6/25), hereditary motor neuropathy (HMN, 7/25) and CMT (indeterminate from  
565 neurophysiology, or no neurophysiology available, 10/25). Within the cases of CMT2/HMN, 38%  
566 (5/13) demonstrate conduction slowing that does not meet criteria for CMTi or CMT1 (upper limb  
567 motor conduction velocities 25-45 m/s) either because the slowing was patchy or subtle, or the  
568 phenotype was HMN. The mean (median) ulnar motor velocity was 42.6 (45) m/s (range 25-58 m/s,  
569 n = 11).

570  
571 It is difficult to comment on disease progression with only a single assessment in many cases, but in  
572 some individuals, from the history there is a more rapid progression than is typical for CMT, with  
573 mean (median) duration between AAO and assessment of 13.0 (5) years; the mean difference is  
574 skewed by some outlying cases of mildly affected relatives. Two cases presented with acute upper  
575 limb weakness. The first (P13 (F12-II:1)), a male infant carrying the recurrent variant p.Leu228His  
576 presented with bilateral upper limb weakness over fifteen days. Spinal imaging was normal, but  
577 neurophysiology was never performed. Upper limb function improved over time, but the patient  
578 sadly died before 5 years of age. The second (P17 (F15-II:2)), a teenage female carrying the recurrent  
579 p.Leu68Pro, presented with acute left-hand weakness, on a background of more widespread  
580 conduction slowing neuropathy. She was treated with intravenous immunoglobulin (Ig) for  
581 presumed chronic inflammatory demyelinating polyneuropathy (CIDP), with no clear response.  
582 Interestingly, P6 (F6-II:7), a female who carries the same homozygous variant, had walking difficulty  
583 from infancy but presented in her teenage years with a four-month deterioration in left lower limb  
584 weakness. She had a conduction slowing neuropathy in the lower limbs. She is currently being  
585 treated with subcutaneous Ig for presumed CIDP.

### 586 587 ***In silico modelling***

588 Multiple sequence alignments performed for ARHGAP19 orthologs across 11 animal species (Figure  
589 2A), anchored to the human ARHGAP19 protein sequence, showed that most variants affect highly  
590 conserved amino acid residues. Of note, the variants affecting moderately conserved residues  
591 (Asn160, Arg407 and Gln415) are frameshift or nonsense. All variants segregated with disease within  
592 the families (Figure 2A). Computational variant prediction tools such as MutationTaster, SIFT and  
593 PolyPhen predict the functional impact of all but two variants as mainly damaging and deleterious.  
594 According to the American College of Medical Genetics and Genomics and the Association for  
595 Molecular Pathology (ACMG-AMP) system for variant classification, all the variants are classified as  
596 either likely pathogenic or pathogenic. The characteristics of all reported variants are summarized in  
597 Supplementary Table 2.

598  
599 Three-dimensional visualisation of ARHGAP19 wild-type and mutant variants as predicted by  
600 AlphaFold2 (Figure 3B) depicts that mutant protein structures for frameshift variants show  
601 substantial deviation from the wild-type protein (Figure 3C), likely disrupting the RhoGAP domain  
602 structure. Nonsense substitutions modelled using AlphaFold2 (Figure 3D) display a similar structure  
603 to the WT protein, with greater variation only occurring in the final alpha-helix and the subsequent  
604 C-terminal end of the protein. Missense substitutions showed little or no change when modelled  
605 with the AlphaFold2 pipeline. As such, the 'mutagenesis' function on PyMol was used to predict  
606 changes in protein structure and/or folding upon substituted amino acid residue incorporation into  
607 the sequence (Figure 3E). All substitutions showed changes in steric hindrance with nearby amino  
608 acid residues. The calculated free energy changes for p.(Gly140Asp), p.(Leu141Trp), p.(Gln151Lys),

609 p.(Leu228His), and p.(Pro311Arg) substitutions show a decrease in free energy >1.6 kcal/mol,  
610 indicating a protein destabilising effect (Figure 3F). Notably, three substitutions are predicted to  
611 result in protein instability with high confidence (p.(Gly140Asp), p.(Leu141Trp), and p.(Pro311Arg)).  
612 In addition, the p.(Gln151Lys) variant shows an increase in free energy and thus an increase in  
613 protein stability. Using further analysis with AlphaMissense, of the nine missense variants identified,  
614 seven (77.78%) are predicted to be likely pathogenic (Supplementary Table 4).

615

## 616 **Functional Characterisation**

### 617 **Western Blotting and qPCR**

618 Given the potential loss of function in homozygous ARHGAP19 individuals, we investigated gene  
619 expression levels through the use of qPCR and protein levels through Western blotting of ARHGAP19  
620 in fibroblasts from families harbouring the c.85A>G (p.Asn29Asp), c.419G>A (p.Gly140Asp), c.203T>C  
621 (p.Leu68Pro) variants and in fibroblast-derived iPSc of P5 (F5-II:2) and P6 (F6-II:7). Whilst gene  
622 expression remained unchanged in both fibroblasts and motor neurones, western blotting  
623 assessment of ARHGAP19 protein levels revealed significant reduction of ARHGAP19 in iPSC motor  
624 neurons of patients as opposed to controls (Figure 4).

625

### 626 **RNA Sequencing**

627 Differential expression analysis showed that there is no difference in ARHGAP19 RNA levels between  
628 the ARHGAP19 deficient patient fibroblasts and healthy controls (log2 fold change = -0.29 and p-  
629 value = 0.43). Thus, we hypothesised that despite having the same expression level, mutant  
630 ARHGAP19 may affect downstream genes in its signalling pathway, causing the disease phenotype.  
631 Principle component analysis (PCA) showed a distinctive RNA expression pattern between the  
632 patients and controls (Supplementary Figure 2). Pathway enrichment analysis showed that the  
633 expression patterns are significantly different in 3 pathways: cell cycle, motor proteins, and muscle  
634 cells' cytoskeleton (Figure 4D). Cellular pathways were further analysed to infer their expression  
635 levels in patients compared to controls, which showed that the 3 mentioned pathways are  
636 downregulated in ARHGAP19 patients (Figure 4E).

### 637 ***In vitro* GAP assay shows loss of GAP activity in ARHGAP19 variants in the GAP domain**

638 ARHGAP19 has been previously reported for its RhoGAP activity. Interestingly, several mutations in  
639 ARHGAP19 are clustering around the region encoding the GAP domain (Figure 1C). To investigate the  
640 GAP activity of these ARHGAP19 variants, the GAP domain of ARHGAP19 or the mutated GAP  
641 proteins were expressed as GST fusion proteins in *E. coli* for *in vitro* GAP assays. Specific GAP activity  
642 toward RhoA was measured as the rate of inorganic phosphate released by GTPase-mediated GTP  
643 hydrolysis. RhoA alone showed little intrinsic GTPase activity, while the addition of wild type  
644 ARHGAP19 significantly accelerated the rate of RhoA-mediated GTP hydrolysis (Figure 5). Two  
645 ARHGAP19 missense mutations, p.Gly140Asp, and p.Gln151Lys, abrogated the GAP activity of  
646 ARHGAP19, decreasing the GTPase hydrolysis rate to the basal level. Another ARHGAP19 mutation,  
647 p.His196Glnfs\*9, which led to a truncated GAP domain of ARHGAP19, completely abolished the GAP  
648 activity as evidenced by severely impaired phosphate release (Figure 5A). Altogether, these results  
649 demonstrate that these mutations in the GAP domain of ARHGAP19 are dominant loss-of-function  
650 alleles, abolishing its GAP activity.

651

### 652 **Patient-derived fibroblast cells demonstrate impaired cell migration**

653 To further analyse the consequences of the ARHGAP19 variants on cellular morphology, we derived  
654 fibroblasts from the patients of family 5 (c.419G>A), family 6 (c.203T>C) and family 10 (c.85A>G),  
655 paired with age/ gender matched health control (wild type). Since the *in vitro* GAP assay indicated  
656 that ARHGAP19 c.419G>A (p.Gly140Asp) show defective GAP activity towards RhoA (Figure 5A), we  
657 hypothesized that variants in ARHGAP19 may affect cell proliferation and migration. ARHGAP19  
658 variants and wild type fibroblasts showed no significant differences in cell proliferation (Figure 5B).  
659 However, patient-derived fibroblasts carrying the Gly140Asp and Asn29Asp mutations had a

660 significant reduction in cell migration compared to control cells using both a Boyden chamber  
661 migration and wound healing assays (Figures 5C and D). In contrast, patient-derived fibroblasts  
662 harbouring the Leu68Pro showed no significant differences with control cells (Figures 5C and D).  
663 These results confirm the GAP defective function of the *ARHGAP19*- Gly140Asp mutant and suggest  
664 that the GAP activity of the *ARHGAP19*-Asn29Asp mutant may also be altered.

### 665 **The *ARHGAP19* ortholog *RhoGAP54D* promotes movement in *Drosophila***

666 To explore the consequences of *ARHGAP19* loss of function *in vivo*, we first utilised the fruit fly,  
667 *Drosophila melanogaster*. The *Drosophila* genome contains a single *ARHGAP19* ortholog termed  
668 *RhoGAP54D*, which exhibits 51% amino-acid similarity and 31% identity to the human *ARHGAP19*  
669 protein (Supplementary Figure 3). To examine the expression of *RhoGAP54D* in the *Drosophila*  
670 nervous system, we utilised a CRIMIC T2A-GAL4 enhancer trap in intron 3 of the *RhoGAP54D* locus  
671 (30), which we term *RhoGAP54D*<sup>CRIMIC-Gal4</sup> and which results in expression of Gal4 in the pattern of  
672 the endogenous gene (Figure 6A). Driving expression of a UAS-*CD4::TdTomato* reporter via  
673 *RhoGAP54D*<sup>CRIMIC-Gal4</sup> allowed us to label *RhoGAP54D*-positive cells in the adult fly brain and thoracic  
674 ganglion (Figure 6B). In agreement with previously published single-cell RNAseq data (31, 32)  
675 (Supplementary Figure 4A), this approach revealed sparse expression of *RhoGAP54D*, including  
676 projections to the antennal mechanosensory motor centre (AMMC) and isolated cell bodies within  
677 the brain and thoracic ganglion (Figure 6B). In addition, we noted *RhoGAP54D*-driven TdTomato  
678 signal surrounding the central and thoracic synaptic regions, suggesting that *RhoGAP54D* may be  
679 expressed in the perineural and/or subperineural glia (SPG) that form the blood-brain barrier  
680 covering the central and thoracic neuropil domains (Figure 6B) (33).

681  
682 Given that *ARHGAP19* variants perturb movement in humans, we tested whether reducing  
683 *RhoGAP54D* expression similarly disrupted movement in *Drosophila*. Since *RhoGAP54D* is likely  
684 expressed in a variety of distinct cell-types, we used a global driver (*actin-Gal4*) in concert with an  
685 shRNA predicted to cleave *RhoGAP54D* mRNA in exon 3 of the primary transcript to induce  
686 ubiquitous *RhoGAP54D* knockdown (Figure 6A). Using quantitative PCR, we confirmed that  
687 expression of this shRNA caused an ~ 50% reduction in *RhoGAP54D* mRNA expression  
688 (Supplementary Figure 4B). We then used the *Drosophila* Activity Monitor (DAM) system (25) to test  
689 how reducing *RhoGAP54D* expression affected locomotor activity in adult flies (Supplementary  
690 Figure 4C). In 12 h light: 12 h dark conditions, wild-type *Drosophila* exhibit crepuscular peaks of  
691 activity centred around lights-on and lights-off, interspersed by periods of low activity (Figure 6C).  
692 Global *RhoGAP54D* knockdown reduced both total activity occurring over 24 h and activity occurring  
693 in the hour following lights-off (zeitgeber time (ZT) 12-13), a measure of peak motor capacity (Figure  
694 6C-E).

695  
696 To complement the above data we utilised degradFP, a genetic system that promotes degradation of  
697 GFP-tagged fusion proteins via the ubiquitin pathway (34). Ubiquitous expression of degradGFP  
698 components in a background homozygote for a *RhoGAP54D::GFP* knock-in allele (22) similarly  
699 reduced overall and peak movement relative to *RhoGAP54D::GFP* homozygote controls (Figure 6F-  
700 H). As a final confirmation of the above results, we generated a *RhoGAP54D* null allele  
701 (*RhoGAP54D*<sup>KO</sup>) through CRISPR-Cas9 gene editing (Figure 6D). Comparison of *RhoGAP54D*<sup>KO</sup>  
702 heterozygote and homozygote flies again revealed reduced overall and peak movement in  
703 *RhoGAP54D*<sup>KO</sup> homozygotes relative to heterozygote controls (Figure 6I-K). Collectively, these data  
704 demonstrate that *RhoGAP54D* promotes robust locomotor activity in *Drosophila*, supporting the  
705 genetic link between variants in the human ortholog *ARHGAP19* and disrupted movement.

### 706 707 ***Danio rerio arhgap19* is important for motor neuron function**

708 We next utilised zebrafish (*Danio rerio*) to examine the molecular, cellular, and developmental  
709 impact of *ARHGAP19* loss of function in a vertebrate system. To analyse the endogenous expression  
710 pattern and subcellular localization of zebrafish *arhgap19* during development, we conducted

711 whole-mount in situ hybridization (WISH) assays at three different embryonic stages, utilizing  
712 digoxigenin-labelled antisense RNA probes specific for *arhgap19*. ISH analyses revealed a ubiquitous  
713 expression pattern of *arhgap19* across multiple brain regions, notably in the forebrain and hindbrain  
714 compartments. This expression was predominantly enriched within neural tissues at the 48 hpf.  
715 Specifically, heightened *arhgap19* expression was observed in anatomically defined regions such as  
716 the cerebrum, thalamus, tuberculum, and tegmentum (Figure 7B). Intriguingly, a temporal  
717 downregulation of *arhgap19* expression was evident as development progressed; by 5 dpf, the  
718 expression levels had substantially diminished (Figure 7B).

719

720 To investigate the functional role of *Arhgap19* in neuronal and motor development, we generated an  
721 F0 biallelic knockout mutant model utilizing CRISPR/Cas9 system. Genomic deletions were  
722 introduced at three selected loci within the zebrafish *arhgap19* gene—exons 2, 4, and 5—informed  
723 by considerations of targeting efficiency and potential off-target effects (Figure 7A). Of the initial  
724 batch of 62 eggs, 32 (51.6%) were successfully fertilized. Embryos were monitored on a daily basis,  
725 with dead ones discarded. Those that survived were sacrificed at 5 dpf for genotyping and  
726 subsequent analysis. NGS sequencing showed that sgRNAs 2, 4, and 5 manifested high gene-editing  
727 efficiency, with respective average modification rates of 96.1%, 99.7% and 94.6%. Conversely, sgRNA  
728 3 exhibited suboptimal performance, achieving a comparatively low modification rate of merely  
729 11%.

730

731 To evaluate the changes in behaviour in the *arhgap19* mutant model, we collected 24 zebrafish  
732 larvae at the 5 dpf and analysed their motor activity. Metrics such as the total duration of  
733 movement, aggregate distance traversed, and mean velocity were measured. Behavioural assays  
734 demonstrated that *arhgap19* knockout induced conspicuous motor deficits. Larvae in both mutant  
735 (CRISPs) groups exhibited decreased motor activity, alongside idiosyncratic and involuntary  
736 movements. In contrast, larvae from the Uninjected Control (UIC) group exhibited normal locomotor  
737 behaviour, exploring the well's periphery (Figure 7C).

738

739 Statistical analysis revealed significant discrepancy in motor parameters among the groups.  
740 Specifically, larvae from both CRISPs groups were significantly different in the total travel  
741 distance (Figure 7D; one-way ANOVA,  $F(2, 69) = 13.954$ , and  $p < 0.0001$ , followed by Welch T test.  
742 CRISPs 0.5nL,  $t(45.82) = -2.376$  and  $p = .022$ ; CRISPs 1nL,  $t(41.939) = -5.418$  and  $p < 0.0001$ ).  
743 Likewise, the mean velocity also showed significant differences between mutant and control groups  
744 (Figure 7E; one-way ANOVA,  $F(2, 69) = 13.954$ , and  $p < 0.0001$ , followed by Welch T test. CRISPs  
745 0.5nL,  $t(45.82) = -2.376$  and  $p = .022$ ; CRISPs 1nL,  $t(41.939) = -5.418$  and  $p < 0.0001$ ). Larvae from  
746 the CRISPs 1nL group swam approximately twice as slow compared to those from the UIC group.

747

748 To investigate the impact of *arhgap19* knockout on muscular architecture, we quantitatively  
749 assessed the birefringence intensity of zebrafish skeletal muscle at the 5-dpf, employing a polarizing  
750 light stereomicroscope for imaging. Statistical analysis of the birefringence levels revealed no  
751 significant difference between the control group and the three knockout groups (Figure 7G; one-way  
752 ANOVA,  $F(2, 8) = 2.904$ ,  $p=0.131$ ). These findings strongly suggest that the skeletal muscle integrity  
753 remains largely intact in the absence of *arhgap19*. Consequently, the motor deficits observed in the  
754 behavioural analyses are more likely attributed to impairments in motor neuron function rather than  
755 muscular deficiencies.

756

757 To investigate the effects of *arhgap19* knockout on primary motor neurons, we employed  
758 immunostaining techniques complemented by confocal microscopy for visualization. Notably, a  
759 more robust axonal bundle was observed in both CRISPs groups (Figure 7H). Quantitative  
760 assessments were carried out to analyze both axonal length and branching complexity. In *arhgap19*  
761 CRISPs larvae, the branching density of the Caudal Primary (CaP) Motorneurons was higher than

762 that of the control group (Figure 5I; one-way ANOVA,  $F(2, 43) = 21.341$  and  $p < 0.0001$ , followed by  
763 Welch T test with Bonferroni's adjustment. CRISPAnt 1nL,  $t(22.271) = 6.33$  and  $***p < 0.0001$ ).  
764 Moreover, axonal length was markedly affected in *arhgap19* CRISPAnts. Statistical analysis revealed  
765 a notable reduction in the average length of CaP and Middle Primary (MiP) motoneurons in 1nL  
766 injected CRISPAnts, measuring 577.2  $\mu\text{m}$  and 391.2  $\mu\text{m}$ , respectively, in contrast to the control  
767 values of 1012.5  $\mu\text{m}$  and 639.8  $\mu\text{m}$ . (Figure 7J; one-way ANOVA,  $F(2, 43) = 41.936$  and  $p < 0.0001$ ,  
768 followed by Welch T test with Bonferroni's adjustment. CRISPAnt 0.5nL,  $t(26.647) = -4.943$  and  $***p$   
769  $< 0.0001$ ; CRISPAnt 1nL,  $t(24.101) = -10.092$  and  $***p < 0.0001$ ) Particularly, the axons of CaPs in  
770 *arhgap19* CRISPAnts exhibited diminished length which failed to reach the ventral musculatures.  
771 Furthermore, embryos injected with *arhgap19* splice site and translation blocking morpholinos also  
772 exhibited branching abnormalities similar to those observed in CRISPAnts mutants (Supplementary  
773 Figure 5). Taken together, these results indicated that impaired motor neuron developmental were  
774 attributable to the loss of *arhgap19*.

775

## 776 Discussion

777 We show that biallelic *ARHGAP19* variants are a novel cause of inherited early-onset neuropathy.  
778 We identified 25 individuals harbouring missense and nonsense variants both within the functional  
779 GAP domain as well as outside this structural domain of *ARHGAP19*. The patients had a motor-  
780 predominant neuropathy with AAO almost exclusively in the first two decades of life. The clinical  
781 phenotype was generally length-dependent, but there are some unusual features including  
782 frequency conduction slowing +/- conduction block, prominent asymmetry, in some individuals  
783 relatively rapid progression and upper limb onset. There was no observable genotype-phenotype  
784 correlation at the first examination; mean AAO of variants in GAP versus non-GAP domain 9.0 vs  
785 11.6 years ( $p = 0.32$ ,  $n = 15$  and 8 respectively) and mean ulnar motor conduction velocity 41.0 vs  
786 44.8 m/s ( $p = 0.62$   $n = 5$  and 5). However, longitudinal studies would help better delineate the  
787 disease progression and any genotype-phenotype correlation.

788

789 Haplotype analysis using genetic data from our cohort as well as from control databases suggested  
790 that p.His196Glnfs\*9 is unlikely to be from a recent common ancestor and possibly suggests that  
791 two independent *ARHGAP19* mutational events within Arabian Middle Eastern populations.  
792 Moreover, p.Gln151Lys and p.Leu68Pro variants are founder effect variants, probably originating in  
793 Turkey given the ethnicity of patients. Variant p.Gln151Lys which affects a highly conserved residue  
794 within the GAP domain, could have a significant structural or functional role. Additionally, this  
795 variant affects the same N-terminal catalytic stretch where the arginine motif at codon 143 is found,  
796 and therefore might have a comparable mechanistic effect as do other *AHRGAP19* variants identified  
797 nearby, i.e. p.Gly140Asp, p.Leu141Trp. Together with p.Leu228His and p.Asn239Lys, they are  
798 predicted to disrupt the domain's structure and subsequently its function as a GTPase-activating  
799 protein in a variety of cellular processes (3, 35). Similarly, previously reported variants in the Rho-  
800 GAP domain of *Myo9b*, abrogate GAP activity (36). Interestingly, the corresponding *MYO9B* gene has  
801 recently been associated with a subtype of CMT2 and isolated optic atrophy (37). Other variants  
802 which increase free energy, such as p.Gln151Lys, may cause a deleterious effect to protein folding or  
803 stability through other mechanism. We note that free energy changes were calculated using the  
804 AlphaFold2-derived *ARHGAP19* protein. A recent study concluded that AlphaFold is not immediately  
805 applicable when calculating free energy changes for predicted protein structures (38). However,  
806 results were based on the first iteration of AlphaFold. Conversely, another study showed that free  
807 energy changes using AlphaFold2-predicted protein models consistently matched those of  
808 experimentally determined structures, particularly in high confidence regions (pLDDT > 90) (13).  
809 Thus, until an experimental *ARHGAP19* protein structure is generated, it is important that *in silico*  
810 investigations of variant impact are complemented by corresponding functional studies.

811



812 The phenotype of conduction slowing in a motor(-predominant) neuropathy is unusual in CMT,  
813 limited to very few genes. Notably, recessive variants in the GEF gene *PLEKHG5* cause this phenotype  
814 and have been showed to cause both loss of large, myelinated fibres and thin myelination seen on  
815 nerve biopsy, and motor axonal degeneration in a knockout mouse model (39, 40). Combined with  
816 the conduction slowing seen with biallelic variants in *ARHGEF10*, mechanistically this would suggest  
817 that Rho GTPase activity, mediated by these GEF and GAP proteins, is implicated in a process that  
818 may involve both myelin and axonal pathologies.

819  
820 Data derived from three global *in vivo* loss-of-function *Drosophila* models and three CRISPR-Cas9  
821 mediated knockout zebrafish models demonstrate a conserved role for ARGHAP19 orthologs in  
822 promoting locomotor activity across metazoan species, supporting the above genotype-phenotype  
823 correlations in human patients harbouring *ARGHAP19* mutations. We observed more pronounced  
824 axonal bundles and a significantly increased number of axonal branches in all experimental mutant  
825 zebrafish groups, suggesting that ARGHAP19 LOF may cause CMT in part by perturbing the  
826 cytoskeleton of motoneurons. This hypothesis is consistent with previous reports of RhoA playing a  
827 critical role in modulating cytoskeletal dynamics, including the mediation of stress fibre formation  
828 and focal adhesions(41), and facilitating axonal outgrowth and branching (42). Further  
829 transcriptomics analysis provided evidence that pathways associated with motor proteins, cell cycle  
830 and muscular cytoskeleton are downregulated, further explaining that clinical features observed in  
831 our patients might be due to alteration in these physiological pathways. Of note, there are some  
832 upregulated cellular functions in the patients, including the ferroptosis and cytokine-cytokine  
833 receptor interactions.

834  
835 How might *ARHGAP19* mutations perturb the cytoskeletal network in motor neurons? In this work,  
836 the pathogenicity of *ARHGAP19* variants p.Gly140Asp, p.Gln151Lys and p.His196Glnfs\*9 are  
837 supported by *in vitro* GAP activity assays which show that variants within GAP domain cause  
838 complete loss of GAP activity. *ARHGAP19* stimulates the intrinsic low GTPase activity of RhoA  
839 thereby negatively regulating the RhoA/ROCK pathway. Variants causing loss of GAP activity of  
840 *ARHGAP19* may therefore cause overactivity of RhoA with further consequences in downstream  
841 effectors such as ROCK activation which has important functions in actin organisation, cell migration,  
842 and axon outgrowth and guidance. Importantly, this is in line with *in vitro* data from patient-derived  
843 fibroblasts harbouring p.Asn29Asp and p. Gly140Asp variants, that show significant decrease in cell  
844 migration using cell migration assays. Together, these results reveal that GAP defective *ARHGAP19*  
845 variants lead to altered RhoA activity thereby altering cell migration and cytoskeletal dynamics.  
846 Interestingly, protein expression analysis by Western blot revealed significant reduction in  
847 *ARHGAP19* in iPSC motor neurons of patients compared to controls. Taken together, our findings are  
848 consistent with the patients' phenotype and functional assays, explaining that the muscular and  
849 motor defects observed in patients as well as animal models could be due to the dysregulation of  
850 the *ARHGAP19* related signalling cascade. We provide evidence for loss-of-function of *ARHGAP19* as  
851 the pathomechanism of the disease and suggest that the loss of function might be more robust in  
852 motor neurons.

853  
854 Of note, variant p.Leu68Pro showed no change in the migration and wound healing assays as  
855 opposed to WT controls. Interestingly, the two patients with this variant in our cohort were first  
856 suspected to have an autoimmune cause of neuropathy and were put on intravenous Ig for  
857 treatment of presumed CIDP with no improvement. These patients also have an upper limb  
858 involvement, and it is noteworthy that even if the variant lies outside the GAP domain, it is predicted  
859 pathogenic using various *in silico* methods.

860  
861 Our findings do not fully elucidate the mechanism of axonal damage caused by *ARHGAP19*  
862 deficiency. Regarding the animal models created in this study, we were not able to investigate the

863 expression of RhoGAP54d in the fly peripheral nervous system and the zebrafish model showed no  
864 expression of the protein ortholog in its periphery. On the basis of frequent conduction slowing and  
865 the early-onset phenotype observed, it will therefore be important to examine peripheral  
866 myelination in the human subjects, as well as use better techniques for spatial localization and  
867 quantitative expression in models of ARHGAP19 deficiency.

868  
869 Despite the theoretically simple on/off switch model of Rho, the Rho GTPase signalling pathway has  
870 a more sophisticated picture. The high number of GAP and GEF proteins – 66 and 80 respectively,  
871 which outnumber Rho proteins, coupled with unclear specificity of the proteins, means that  
872 understating their signalling activities as well as role in disease, remain challenging. Nevertheless,  
873 overactive RhoA signalling in neurons, be it due to genetic variations or imbalance between  
874 signalling molecules, has been reported in Charcot-Marie-Tooth disease. It is increasingly emerging  
875 that this is an important pathway not only in neuronal health but also in disease. Hence, modulation  
876 of this pathway may represent a potential strategy for future therapeutic treatments.

877

### 878 **Acknowledgments**

879 We thank the patient and relatives for consent to be part of the study as well as the clinicians for  
880 helping with patient phenotyping. The families were collected as part of the SYNAPS Study Group  
881 collaboration funded by The Wellcome Trust and strategic award (Synaptopathies) funding  
882 (WT093205 MA and WT104033AIA) and research was conducted as part of the Queen Square  
883 Genomics group at University College London, supported by the National Institute for Health  
884 Research University College London Hospitals Biomedical Research Centre. This work was partly  
885 supported by an MRC strategic award to establish an International Centre for Genomic Medicine in  
886 Neuromuscular Diseases (ICGNMD) MR/S005021/1 and ND, SE, CR, PT, MGH, MMR and HH received  
887 direct support from this award. JP is supported by Medical Research Future Fund (MRFF) Genomics  
888 Health Futures Mission (APP2007681) and by the Australian Government Research Training  
889 Program. LVdV is supported by a predoctoral fellowship of the Research Fund - Flanders (FWO)  
890 under grant agreement N°11F0921N. TS is member of the European Reference Network for Rare  
891 Neuromuscular Diseases (ERN EURO-NMD). JB is supported by a Senior Clinical Researcher mandate  
892 of the Research Fund - Flanders (FWO) under grant agreement N°1805021N. ANB gratefully  
893 acknowledges the support of SVIKV and the use of the services and facilities of the Koç University  
894 Research Center for Translational Medicine (KUTTAM), funded by the Presidency of Turkey, Head of  
895 Strategy and Budget. We thank collaborator Simon Bullock (University of Cambridge) for plasmids,  
896 and Florencia di Pietro for characterization of the RhoGAP54D loss of function allele. JECJ was  
897 funded by an MRC Senior Non-Clinical Fellowship (MR/V03118X/1). Work in the Bellaïche group is  
898 funded by the CNRS, the INSERM and the Institut Curie as well as by the ANR (TiMecaDiv  
899 20CE13000801) grant. TBH was supported by the Deutsche Forschungsgemeinschaft (DFG, German  
900 Research Foundation – 418081722, 433158657), and the European Commission (Recon4IMD - GAP-  
901 101080997). This work was supported in part by the Fund for Scientific Research (FWO-Flanders)  
902 (research grants G048220N and G0A2122N to A.J.), the Research Fund of the University of Antwerp  
903 (doctoral grant to C.A.), the Association Belge contre les Maladies Neuromusculaires' (ABMM-  
904 Telethon) (research grantsto A.J.), the French Muscular Dystrophy Association (AFM-Telethon,  
905 research grant 23708 to A.J.). JPark was supported by the Clinician Scientist program "PRECISE.net"  
906 funded by the Else Kröner-Fresenius-Stiftung. Work in the Lamarche-Vane group funded by Natural  
907 Sciences and Engineering Research Council of Canada grant RGPIN/04809-2017 and CIHR project  
908 grant PJT-180367. Leif Leclair holds a CIHR master studentship. RH is supported by the Wellcome  
909 Discovery Award (226653/Z/22/Z), the Medical Research Council (UK) (MR/V009346/1), the  
910 Addenbrookes Charitable Trust (G100142), the Evelyn Trust, the Stoneygate Trust, the Lily  
911 Foundation, Ataxia UK, Action for AT, the Muscular Dystrophy UK. This research was supported by  
912 the NIHR Cambridge Biomedical Research Centre (BRC-1215-20014). The views expressed are those  
913 of the authors and not necessarily those of the NIHR or the Department of Health and Social

914 Care. We are also grateful to Queen Square Genomics at the Institute of Neurology University College  
 915 London, supported by the National Institute for Health Research University College London Hospitals  
 916 Biomedical Research Centre, for the bioinformatics support.

917

918 **Online resources**

919 CPDB web tool, <http://cpdb.molgen.mpg.de/>

920 Ensembl, <http://www.ensembl.org/i>

921 FastQC, <http://www.bioinformatics.babraham.ac.uk/projects/fastqc/>

922 GATK documentation, <https://software.broadinstitute.org/gatk/>

923 Human Genome Variation Society, <http://www.hgvs.org>

924 Mutation Taster version 2, <http://www.mutationtaster.org/>

925 PolyPhen-2, <http://genetics.bwh.harvard.edu/pph2/>

926 SIFT, <http://sift.jcvi.org/>

927 University of California—San Francisco (UCSC) Genome Browser, <https://genome.ucsc.edu/>

928 Jalview, <https://www.jalview.org/>

929 UniProt, <https://www.uniprot.org/>

930 PyMol, <https://pymol.org/2/>


931 AlphaFold Protein Structure Database, <https://alphafold.ebi.ac.uk/>

932 FoldX, <https://foldxsuite.crg.eu/>

933 DIOPT <http://flybase.org/reports/FBgn0034249.html>

934

935 **Figures**




936

937 **Figure 1. A.** Pathway showing GTPase-activating proteins (GAPs) such as ARHGAP19 responsible for

938 promoting cycling of Rho GTPases between the active GTP-bound and the inactive GDP-bound

939 conformations. GEF: Guanine nucleotide Exchange Factor, GDP: Guanine nucleotide diphosphate,  
 940 GDI: Guanine Nucleotide Dissociation Inhibitor, Pi: dihydrogen phosphate. **B-C.** Schematic diagrams  
 941 of ARHGAP19 gene (B) and protein (C). Introns are not to scale. Exon numbers are according to the  
 942 canonical transcript (NM\_032900.6). Amino acid changes are according to the reference sequence  
 943 NP\_116289.4.




944

945 **Figure 2. Genetic presentation of individuals harbouring ARHGAP19 variants.** Pedigrees of affected  
 946 families showing segregation of the biallelic ARHGAP19 variants identified.


947

948



949


950 **Figure 3. Investigating the effect of *ARHGAP19* variants *in silico*.** **A.** Multiple sequence alignment of  
 951 *ARHGAP19* orthologs shows conservation of identified variants in different species. **B.** Predicted  
 952 wild-type *ARHGAP19* protein structure (UniProt: Q14CB8) using AlphaFold2, coloured with the per-  
 953 residue confidence score (pLDDT). Dark blue, very high confidence (pLDDT > 90); light blue,  
 954 confident (90 > pLDDT > 70); yellow, low confidence (70 > pLDDT > 50); orange, very low confidence  
 955 (pLDDT < 50). AlphaFold-generated mutant protein structures (red) derived from the identified  
 956 frameshift **C.** and nonsense **D.** variants and aligned to the wild-type *ARHGAP19* protein (green). **E.**  
 957 The effect of identified missense variants on three-dimensional *ARHGAP19* structure. Wild-type  
 958 residues are coloured green and mutant residues are coloured red. **F.** Predicted free energy changes  
 959 ( $\Delta GMUT - \Delta GWT$ ) for missense variants on protein stability. Calculations were performed on  
 960 variants within the very high confidence regions (pLDDT >90) of the AlphaFold-generated *ARHGAP19*  
 961 protein. Data are given as mean  $\pm$  s.d.  
 962



963 **Figure 4. Western blot and RNA-Seq analyses confirm downregulation of *ARHGAP19* as well as cell**  
 964 **cycle, motor and muscular cytoskeleton pathways.** **A-B.** Protein expression levels of *ARHGAP19* in  
 966 iPSc-derived motor neuronal lines (A) and patient-derived fibroblasts (B). Fibroblasts from P5 (F5-  
 967 II:2), P6 (F6-II:7) and P11 (F10-II:1) harbouring the c.419G>A (p.Gly140Asp), c.203T>C (p.Leu68Pro)  
 968 and c.85A>G (p.Asn29Asp) variants respectively were analysed by Western blot, as well as fibroblast-  
 969 derived iPSc neurons from P5 (F5-II:2) and P6 (F6-II:7) patients. **C.** Volcano plot showing log2 of fold  
 970 change in *ARHGAP19* mutants compared to controls and  $-\log_{10}$  (adjusted p value). **D.** Pathway  
 971 enrichment: differentially expressed genes with p-value < 0.005 were selected for performing  
 972 pathways enrichment analysis. Top 10 pathways with the highest enrichment scores were plotted,  
 973 showing 3 cellular pathways highly enriched with dozens of affected genes and a very low p-value:  
 974 cell cycle, motor proteins, and cytoskeleton in muscle cells. **E.** Pathway scores per sample: enriched


975 pathways were analysed to compare their expression levels in patients and controls. Some pathways  
 976 are overexpressed in patients while most of them are downregulated.

977



978 **Figure 5. ARHGAP19 variants have defective GAP-activity and cell migration. A.** *In vitro* GAP activity  
 979 assay measuring the GTPase rate of RhoA in the absence (intrinsic) or the presence of GAP domain  
 980 from ARHGAP19 wild type (WT) or mutants. Data are presented as means  $\pm$  SEM from three  
 981 independent experiments ( $n=3$ ; \*\*\*\*,  $p<0.0001$ ; one-way ANOVA) **B.** MTT assays in fibroblasts from  
 982 healthy controls (wt#223 and wt#1419) and ARHGAP19 mutants ( $n=3$ ). **C and D.** Fibroblasts cells  
 983 were subjected to the Boyden chamber migration assay (C) or wound healing scratch assay (D) as  
 984 described in Materials and methods ( $n=4$ ). Data are presented as means  $\pm$  SEM (\* $p<0.05$ , \*\* $p<0.01$ ,  
 985 ns, not significant, one-way ANOVA)


987



988  
 989 **Figure 6. ARHGAP19 ortholog *RhoGAP54D* promotes movement in *Drosophila melanogaster*.** **A.**  
 990 Schematic of the *RhoGAP54D* locus. Exons – white blocks; untranslated regions (UTRs) – grey blocks;  
 991 introns – line. Insertion site of the *RhoGAP54D*<sup>CRIMIC-Gal4</sup> element and exonic region targeted by  
 992 *RhoGAP54D* shRNA are shown (red arrows). **B.** Confocal images illustrating *RhoGAP54D*-driven  
 993 membrane-tagged CD4::TdTomato expression in the adult male *Drosophila* brain and thoracic  
 994 ganglion. Brain: yellow arrow points to projections close to the antennal mechanosensory motor  
 995 ganglion. Thoracic ganglion: red arrows point to isolated cell bodies. Note the CD4::TdTomato signal

996 surrounding Bruchpilot (BRP)-labelled neuropil domains. **C.** Patterns of locomotor activity in flies  
997 globally expressing *RhoGAP54D* shRNA (*actin > RhoGAP54D* shRNA) and driver/shRNA alone  
998 controls. White bar: lights on; black bar: lights off. **D-E.** Number of beam breaks across 24 h (**D**) or  
999 during ZT12-13 (**E**), a period of peak activity. n = 15-16. **F-H.** Patterns of locomotor activity (**F**), total  
1000 (**G**) and peak (ZT12-13; **H**) beam breaks in adult flies harbouring a *RhoGAP54D* GFP fusion allele and  
1001 expressing deGradFP components, enabling degradation of the RhoGAP54D::GFP fusion protein, and  
1002 a *RhoGAP54D*::GFP homozygote control. N = 18 and 24 respectively. **I-K.** Patterns of locomotor  
1003 activity (**I**), total (**J**) and peak (ZT12-13; **K**) beam breaks in adult flies heterozygous or homozygous for  
1004 the *RhoGAP54D*<sup>KO</sup> null allele. N = 16 and 20 respectively. Central line in dot plots: mean. Error bars:  
1005 standard error of the mean (SEM). \* P < 0.05, \*\*P < 0.005, \*\*\*P < 0.0005, one-way ANOVA with  
1006 Dunnett's post-hoc test (D), Kruskal-Wallis test with Dunn's post-hoc test (E), Mann-Whitney U-test  
1007 (G, K), or t-test with Welch's correction (H, J)  
1008





1009

1010

1011

1012

1013

1014

1015

1016

1017

1018

1019

1020

1021

**Figure 7. *Danio rerio arhgap19* is important for motor neuron function. A.** Schematic

representation of ten exons to cover the complete coding region. The position of the sgRNA targets

are indicated (green illustrate the highest level of knockdown efficiency). **B.** *arhgap19* expression at

three different embryonic stages in zebrafish. At 48 hpf, WISH signal of *arhgap19* is localized in the

forebrain and hindbrain regions; scale bar = 1000 µm. Rho: Rhombencephalon (hindbrain); Tel:

Telencephalon; Th: Thalamus; Tu: Tuberculum; Tgm: Tegmentum. **C-E.** Behavior analysis of UIC and

*arhgap19* mutant zebrafish larvae at 5-dpf. (C) reveals the swimming trajectories of each larva.

Quantification of total travel distance (D) and travel velocity (E) of UIC and *arhgap19* mutant

zebrafish larvae for 30 mins (UIC, CRISPant 0.5nL, CRISPant 1nL: n = 24). Each bar represents mean (±

SEM). Asterisks above the bars indicate significant difference (\*P ≤ 0.05, \*\*P ≤ 0.01, \*\*\*P ≤ 0.001). **F-**

**G.** UIC and *arhgap19* mutant zebrafish larvae at 5-dpf were evaluated for muscle integrity using

birefringence. (F) A representative image of one larva from each treatment group; scale bar = 1000

1022  $\mu\text{m}$ . Each bar in plot (G) represents average birefringence ( $\pm$  SEM) for all zebrafish larvae (UIC,  
1023 CRISPa<sub>nt</sub> 0.5nL, CRISPa<sub>nt</sub> 1nL : n = 3). **H-J**. Spinal motor neurons morphogenesis defects in *arhgap19*  
1024 mutant zebrafish larvae. (H) Confocal imaging analysis and three-dimensional reconstruction of  
1025 spinal motor neurons in UIC and *arhgap19* mutant groups at 5-dpf; scale bar = 100  $\mu\text{m}$ . (I) Axonal  
1026 branching number of Cap axons in UIC and *arhgap19* mutant zebrafish larvae. (J) Average axonal  
1027 length of Cap (yellow) and Mip (blue) axons in UIC and *arhgap19* mutant zebrafish larvae. Each bar  
1028 represents mean ( $\pm$  SEM). Asterisks above the bars indicate significant difference (\* $P \leq 0.05$ , \*\* $P \leq$   
1029 0.01, \*\*\* $P \leq 0.001$ , \*\*\*\* $P \leq 0.0001$ ).

1030

## 1031 References

- 1032 1. Pisciotta C, Shy ME. Neuropathy. *Handb Clin Neurol*. 2018;148:653-65.
- 1033 2. Klein CJ. Charcot-Marie-Tooth Disease and Other Hereditary Neuropathies. *Continuum*  
1034 (Minneap Minn). 2020;26(5):1224-56.
- 1035 3. David MD, Petit D, Bertoglio J. The RhoGAP ARHGAP19 controls cytokinesis and  
1036 chromosome segregation in T lymphocytes. *J Cell Sci*. 2014;127(Pt 2):400-10.
- 1037 4. Niftullayev S, Lamarche-Vane N. Regulators of Rho GTPases in the Nervous System:  
1038 Molecular Implication in Axon Guidance and Neurological Disorders. *International journal of*  
1039 *molecular sciences*. 2019;20(6).
- 1040 5. Chen Z, Maroofian R, Basak AN, Shingavi L, Karakaya M, Efthymiou S, et al. Novel variants  
1041 broaden the phenotypic spectrum of PLEKHG5-associated neuropathies. *European journal of*  
1042 *neurology*. 2021;28(4):1344-55.
- 1043 6. Marceaux C, Petit D, Bertoglio J, David MD. Phosphorylation of ARHGAP19 by CDK1 and  
1044 ROCK regulates its subcellular localization and function during mitosis. *J Cell Sci*. 2018;131(5).
- 1045 7. Efthymiou S, Salpietro V, Malintan N, Poncelet M, Kriouile Y, Fortuna S, et al. Biallelic  
1046 mutations in neurofascin cause neurodevelopmental impairment and peripheral demyelination.  
1047 *Brain : a journal of neurology*. 2019;142(10):2948-64.
- 1048 8. Quinodoz M, Peter VG, Bedoni N, Royer Bertrand B, Cisarova K, Salmaninejad A, et al.  
1049 AutoMap is a high performance homozygosity mapping tool using next-generation sequencing data.  
1050 *Nature communications*. 2021;12(1):518.
- 1051 9. Gandolfo LC, Bahlo M, Speed TP. Dating rare mutations from small samples with dense  
1052 marker data. *Genetics*. 2014;197(4):1315-27.
- 1053 10. Jumper J, Evans R, Pritzel A, Green T, Figurnov M, Ronneberger O, et al. Highly accurate  
1054 protein structure prediction with AlphaFold. *Nature*. 2021;596(7873):583-9.
- 1055 11. Cheng J, Novati G, Pan J, Bycroft C, Zemgulyte A, Applebaum T, et al. Accurate proteome-  
1056 wide missense variant effect prediction with AlphaMissense. *Science (New York, NY)*.  
1057 2023;381(6664):eadg7492.
- 1058 12. Delgado J, Radusky LG, Cianferoni D, Serrano L. FoldX 5.0: working with RNA, small  
1059 molecules and a new graphical interface. *Bioinformatics (Oxford, England)*. 2019;35(20):4168-9.
- 1060 13. Akdel M, Pires DEV, Pardo EP, Janes J, Zalevsky AO, Meszaros B, et al. A structural biology  
1061 community assessment of AlphaFold2 applications. *Nat Struct Mol Biol*. 2022;29(11):1056-67.
- 1062 14. Ravenscroft G, Miyatake S, Lehtokari VL, Todd EJ, Vornanen P, Yau KS, et al. Mutations in  
1063 KLHL40 are a frequent cause of severe autosomal-recessive nemaline myopathy. *Am J Hum Genet*.  
1064 2013;93(1):6-18.
- 1065 15. Mao K, Borel C, Ansar M, Jolly A, Makrythanasis P, Froehlich C, et al. FOXI3 pathogenic  
1066 variants cause one form of craniofacial microsomia. *Nature communications*. 2023;14(1):2026.
- 1067 16. Rizzo F, Bono S, Ruepp MD, Salani S, Ottoboni L, Abati E, et al. Combined RNA interference  
1068 and gene replacement therapy targeting MFN2 as proof of principle for the treatment of Charcot-  
1069 Marie-Tooth type 2A. *Cell Mol Life Sci*. 2023;80(12):373.
- 1070 17. He Y, Goyette MA, Chapelle J, Boufaied N, Al Rahbani J, Schonewolff M, et al. CdGAP is a  
1071 talin-binding protein and a target of TGF- $\beta$  signaling that promotes HER2-positive breast cancer  
1072 growth and metastasis. *Cell Rep*. 2023;42(8):112936.

- 1073 18. Dobin A, Davis CA, Schlesinger F, Drenkow J, Zaleski C, Jha S, et al. STAR: ultrafast universal  
1074 RNA-seq aligner. *Bioinformatics*. 2013;29(1):15-21.
- 1075 19. Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for RNA-  
1076 seq data with DESeq2. *Genome Biol*. 2014;15(12):550.
- 1077 20. Ulgen E, Ozisik O, Sezerman OU. pathfindR: An R Package for Comprehensive Identification  
1078 of Enriched Pathways in Omics Data Through Active Subnetworks. *Front Genet*. 2019;10:858.
- 1079 21. Stewart K, Gaitan Y, Shafer ME, Aoudjit L, Hu D, Sharma R, et al. A Point Mutation in p190A  
1080 RhoGAP Affects Ciliogenesis and Leads to Glomerulocystic Kidney Defects. *PLoS genetics*.  
1081 2016;12(2):e1005785.
- 1082 22. di Pietro F, Osswald M, De Las Heras JM, Cristo I, Lopez-Gay J, Wang Z, et al. Systematic  
1083 analysis of RhoGEF/GAP localizations uncovers regulators of mechanosensing and junction formation  
1084 during epithelial cell division. *Current biology : CB*. 2023;33(5):858-74 e7.
- 1085 23. Pinheiro D, Hannezo E, Herszterg S, Bosveld F, Gaugue I, Balakireva M, et al. Transmission of  
1086 cytokinesis forces via E-cadherin dilution and actomyosin flows. *Nature*. 2017;545(7652):103-7.
- 1087 24. Port F, Bullock SL. Augmenting CRISPR applications in *Drosophila* with tRNA-flanked sgRNAs.  
1088 *Nature methods*. 2016;13(10):852-4.
- 1089 25. Pfeiffenberger C, Lear BC, Keegan KP, Allada R. Locomotor activity level monitoring using the  
1090 *Drosophila* Activity Monitoring (DAM) System. *Cold Spring Harb Protoc*. 2010;2010(11):pdb  
1091 prot5518.
- 1092 26. Wu JS, Luo L. A protocol for dissecting *Drosophila melanogaster* brains for live imaging or  
1093 immunostaining. *Nat Protoc*. 2006;1(4):2110-5.
- 1094 27. Coutelle O, Blagden CS, Hampson R, Halai C, Rigby PW, Hughes SM. Hedgehog signalling is  
1095 required for maintenance of myf5 and myoD expression and timely terminal differentiation in  
1096 zebrafish adaxial myogenesis. *Dev Biol*. 2001;236(1):136-50.
- 1097 28. Kroll F, Powell GT, Ghosh M, Gestri G, Antinucci P, Hearn TJ, et al. A simple and effective FO  
1098 knockout method for rapid screening of behaviour and other complex phenotypes. *Elife*. 2021;10.
- 1099 29. Clement K, Rees H, Canver MC, Gehrke JM, Farouni R, Hsu JY, et al. CRISPResso2 provides  
1100 accurate and rapid genome editing sequence analysis. *Nat Biotechnol*. 2019;37(3):224-6.
- 1101 30. Lee PT, Zirin J, Kanca O, Lin WW, Schulze KL, Li-Kroeger D, et al. A gene-specific T2A-GAL4  
1102 library for *Drosophila*. *Elife*. 2018;7.
- 1103 31. Davie K, Janssens J, Koldere D, De Waegeneer M, Pech U, Kreft L, et al. A Single-Cell  
1104 Transcriptome Atlas of the Aging *Drosophila* Brain. *Cell*. 2018;174(4):982-98 e20.
- 1105 32. Allen AM, Neville MC, Birtles S, Croset V, Treiber CD, Waddell S, et al. A single-cell  
1106 transcriptomic atlas of the adult *Drosophila* ventral nerve cord. *Elife*. 2020;9.
- 1107 33. Freeman MR. *Drosophila* Central Nervous System Glia. *Cold Spring Harb Perspect Biol*.  
1108 2015;7(11).
- 1109 34. Caussinus E, Kanca O, Affolter M. Fluorescent fusion protein knockout mediated by anti-GFP  
1110 nanobody. *Nat Struct Mol Biol*. 2011;19(1):117-21.
- 1111 35. Amin E, Jaiswal M, Derewenda U, Reis K, Nouri K, Koessmeier KT, et al. Deciphering the  
1112 Molecular and Functional Basis of RHOGEF Family Proteins: A SYSTEMATIC APPROACH TOWARD  
1113 SELECTIVE INACTIVATION OF RHO FAMILY PROTEINS. *The Journal of biological chemistry*.  
1114 2016;291(39):20353-71.
- 1115 36. Hemkemeyer SA, Vollmer V, Schwarz V, Lohmann B, Honnert U, Taha M, et al. Local Myo9b  
1116 RhoGAP activity regulates cell motility. *The Journal of biological chemistry*. 2021;296:100136.
- 1117 37. Cipriani S, Guerrero-Valero M, Tozza S, Zhao E, Vollmer V, Beijer D, et al. Mutations in  
1118 MYO9B are associated with Charcot-Marie-Tooth disease type 2 neuropathies and isolated optic  
1119 atrophy. *European journal of neurology*. 2023;30(2):511-26.
- 1120 38. Pak MA, Markhieva KA, Novikova MS, Petrov DS, Vorobyev IS, Maksimova ES, et al. Using  
1121 AlphaFold to predict the impact of single mutations on protein stability and function. *PLoS One*.  
1122 2023;18(3):e0282689.

- 1123 39. Azzedine H, Zavadakova P, Plante-Bordeneuve V, Vaz Pato M, Pinto N, Bartesaghi L, et al.  
1124 PLEKHG5 deficiency leads to an intermediate form of autosomal-recessive Charcot-Marie-Tooth  
1125 disease. *Hum Mol Genet.* 2013;22(20):4224-32.
- 1126 40. Luningschror P, Binotti B, Dombert B, Heimann P, Perez-Lara A, Slotta C, et al. Plekhg5-  
1127 regulated autophagy of synaptic vesicles reveals a pathogenic mechanism in motoneuron disease.  
1128 *Nat Commun.* 2017;8(1):678.
- 1129 41. Chrzanowska-Wodnicka M, Burridge K. Rho-stimulated contractility drives the formation of  
1130 stress fibers and focal adhesions. *J Cell Biol.* 1996;133(6):1403-15.
- 1131 42. Chen H, Firestein BL. RhoA regulates dendrite branching in hippocampal neurons by  
1132 decreasing cypin protein levels. *J Neurosci.* 2007;27(31):8378-86.

1133

Family	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20
<b>Case</b>	PT1 (F1- II:1)	PT2 (F2- II:5)	PT3 (F3- II:1)	PT4 (F4- II:1)	PT5 (F5- II:2)	PT6 (F6- II:7)	PT7 (F7- II:1)	PT8 (F8- II:2)	PT9 (F9- II:3)	PT11 (F10- II:1)	PT12 (F11- II:2)	PT13 (F12- II:1)	PT14 (F13- II:3)	PT15 (F14- II:2)	PT17 (F15- II:2)	PT18 (F16- II:1)	PT19 (F17- II:1)	PT20 (F18- II:1)	PT21 (F19- II:1)	PT25 (F21-IV:1)
<b>Nucleotide change</b>	c.261dup	c.585dupA	c.1243C>T	c.1219C>T	c.419G>A	c.203T>C	c.451C>A	c.1A>G	c.452del	c.85A>G	c.932C>G	c.683T>A	c.585dupA	c.451C>A	c.203T>C	c.422T>G	c.717T>A	c.563del	c.683T>A	c.818C>T
<b>Amino acid change</b>	p.Pro88Alafs*43	p.His196Glnfs*9	p.Gln415*	p.Arg407*	p.Gly140Asp	p.Leu68Pro	p.Gln151Lys	p.Met1?	p.Asn160Metfs*21	p.Asn29Asp	p.Pro311Arg	p.Leu228His	p.His196Glnfs*9	p.Gln151Lys	p.Leu68Pro	p.Leu141Trp	p.Asn239Lys	p.Pro188Argfs*5	p.Leu228His	p.Pro273Leu
<b>Sex</b>	M	M	F	F	M	F	F	F	M	M	M	M	F	M	F	F	F	F	M	F
<b>Phenotype</b>	CMT-MP**	CMT with CS*	dHMN with CS	CMT2-MP	dHMN	dHMN with CS	CMT with CS*	CMT2-MP	CMT2with CS**	CMT2-MP	CMT2-MP with CS	Unk*	CMT**	dHMN*	CMTi-MP	dHMN**	CMT with CS*	HMN with CS**	CMT2-MP	dHMN*
<b>Consanguinity</b>	Yes	No	Yes	No	No	Yes	No	Yes	Yes	Yes	Yes	Yes	Yes	Yes	No	No	Yes	Yes	Yes	Yes
<b>Age of onset (years)</b>	6-10	11-15	6-10	6-10	10-20	infancy	11-15	11-15	11-15	26-30	11-15	0-5	n/a	11-15	11-15 <sup>Δ</sup>	11-15	6-10	6-10	11-15	0-5
<b>Symptom at onset</b>	Falls	Walking difficulty	Falls	Dist LL weakness	Dist LL weakness	Walking difficulty	Dist LL weakness	Walking difficulty	Dist right LL weakness	Leg cramps	Dist LL weakness	Acute UL weakness	Unk	Falls	Acute left hand weakness	Dist LL weakness	Right leg weakness	Dist right LL weakness	Dist left LL weakness	Dist LL weakness
<b>Asymmetry</b>	Yes	Yes	Yes	No	No	Yes	No	Yes	Yes	No	No	No	Unk	No	Yes	Yes	Yes	Yes	Yes	Yes
<b>Clinical sensory involvement</b>	No	Yes	No	Yes	No	Yes	No	Yes	Yes	Yes	Yes	Yes	Unk	No	Yes	Yes	Unk	No	No	Yes
<b>LL Areflexia</b>	No	Brisk KJ, AJ	Yes	Yes	Yes	KJ present	Yes	KJ present	Yes	KJ brisk, AJ present, L Babinski	KJ present	Unk	Unk	Yes	Brisk KJ, AJ present	Yes	Left AJ present	Yes	No	KJ present

<b>Pattern of muscle weakness( MRC grade ADF/APF)</b>	Dist LL L>R (4,3/4, 4)	Distal LL L>R (1,2)	LD (~3,0/4 )	LD ('severe')	LL predominant dist > prox (0/0)	LD (~2,3/4 )	LD (4/4)	LD (0/4)	LD (~1,3/5 )	LL predominant dist > prox (4/5)	LD (0/3)	UL > LL (Unk)	Unk	?LD (Unk)	Dist UL> LL (5/5)	LD (0,1/1)	Right dist LL only (Unk)	LL predominant dist > prox (~1/?)	Dist LL L>R, (4,0/5)	LD (2/4)
<b>Foot deformity</b>	Pes cavus	Pes planus, hammer toe	Pes cavus	Pes cavus	Nil	Pes cavus, SG	Pes cavus	Pes planus	Pes planus	Nil	Pes cavus	Nil	Unk	Pes cavus	Hammer toe, SG	Pes cavus	Unk	Unk	No	Yes
<b>Gait</b>	Left foot drop	Unk	Steppage	Unk	Steppage	Steppage	Steppage	Steppage	Steppage	Steppage and waddle	Steppage	Unclear	Unk	Steppage	Normal	Steppage	Unk	Steppage	Steppage	Steppage
<b>Muscle atrophy</b>	Dist LL L>R	Distal LL (calf hypertrophy)	Calves down	Dist LL	Calves down	Feet	Feet	Calves down	None	Calves down	Dist LL	Unk	Unk	Dist LL	Hands and dist LL	Dist UL and LL	Unk	Dist LL R>L	Dist LL	Dist LL > UL
<b>Neurophysiology</b>	Limited study: LL motor only. Asymmetric LD motor neuropathy	*Axonal and demyelinating neuropathy (mainly axonal) bilaterally, L>R	LD motor neuropathy with significant conduction slowing and block	LD MP axonal neuropathy	MP LL predominant axonal neuropathy	MP LL predominant axonal neuropathy with some conduction slowing	*Mixed axonal and demyelinating neuropathy (mainly axonal) UL and LL	LD MP axonal neuropathy with upper limb asymmetry	Very limited study; LD sensory and motor neuropathy	LD axonal neuropathy, some acute EMG changes	LD MP axonal neuropathy with conduction slowing	Not performed	Very limited only single nerve studied	*motor axonal neuropathy	LD MP demyelinating neuropathy	Limited study; MPLD neuropathy	*Mixed motor> sensory neuropathy (axonal >demyelinating) involving both LL, R>L	**Motor neuropathy with conduction slowing	LD MP axonal neuropathy with minimal conduction slowing	*Axonal motor neuropathy

**Table 1. Clinical features of ARHGAP19 individuals.** MP motor predominant \* neurophysiology data not seen +/- report available only \*\* very limited study, Clinical sensory involvement refers to symptoms and/or signs. Δ assessed approximately 2 years after onset of acute left hand weakness. CS conduction slowing LL lower limb UL upper limb KJ knee jerk, AJ ankle jerk, SG increased sandal gap, MRC grade ADF/APF = medical research council power grading of power in ankle dorsiflexion/ankle plantar flexion. ~ = approximate (where known). If there is discrepancy between limbs, a comma separates right and left. > greater than, LD length-dependent, M male, F female, Unk unknown, dist distal, prox proximal.